MIRA INFORM REPORT
|
Report No. : |
344192 |
|
Report Date : |
10.10.2015 |
IDENTIFICATION DETAILS
|
Name : |
SMITHKLINE BEECHAM SA |
|
|
|
|
Registered Office : |
CL. Severo Ochoa, 2 Parque Tecnologico De Madrid - Tres Cantos - 28760
- Madrid |
|
|
|
|
Country : |
Spain |
|
|
|
|
Financials (as on) : |
2014 |
|
|
|
|
Date of Incorporation : |
26.09.1977 |
|
|
|
|
Legal Form : |
Public Company |
|
|
|
|
Line of Business : |
Subject is manufacture of pharmaceutical preparations |
|
|
|
|
No. of Employee : |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Spain |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SPAIN - ECONOMIC OVERVIEW
After experiencing a prolonged recession in the wake of the global financial crisis that began in 2008, in 2014 Spain marked the first full year of positive economic growth in seven years, largely due to increased private consumption. At the onset of the global financial crisis Spain's GDP contracted by 3.7% in 2009, ending a 16-year growth trend, and continued contracting through most of 2013. In 2013 the government successfully shored up struggling banks - exposed to the collapse of Spain's depressed real estate and construction sectors - and in January 2014 completed an EU-funded restructuring and recapitalization program.
Until 2014, credit contraction in the private sector, fiscal austerity, and high unemployment weighed on domestic consumption and investment. The unemployment rate rose from a low of about 8% in 2007 to more than 26% in 2013, but labor reforms prompted a modest reduction to 23.7% in 2014. High unemployment strained Spain's public finances, as spending on social benefits increased while tax revenues fell. Spain’s budget deficit peaked at 11.4% of GDP in 2010, but Spain gradually reduced the deficit to just under 7% of GDP in 2013-14, slightly above the 6.5% target negotiated between Spain and the EU. Public debt has increased substantially – from 60.1% of GDP in 2010 to more than 97% in 2014.
Exports were resilient throughout the economic downturn and helped to bring Spain's current account into surplus in 2013 for the first time since 1986, where it remained in 2014. Rising labor productivity and an internal devaluation resulting from moderating labor costs and lower inflation have helped to improve foreign investor interest in the economy and positive FDI flows have been restored.
The government's efforts to implement labor, pension, health, tax, and education reforms - aimed at supporting investor sentiment - have become overshadowed by political activity in 2015 in anticipation of the national parliamentary elections in November. Spain’s 2015 budget, published in September 2014, rolls back some recently imposed taxes in advance of the elections and leaves untouched the country’s value-added tax (VAT) regime, which continues to generate significantly lower revenue than the EU average. Spain’s borrowing costs are dramatically lower since their peak in mid-2012, and despite the recent uptic in economic activity, inflation has dropped sharply, from 1.5% in 2013 to nearly flat in 2014.
|
Source
: CIA |
|
EXECUTIVE
SUMMARY
|
|
|
|
|
|
Name: |
SMITHKLINE
BEECHAM SA |
|
NIF
/ Fiscal code: |
A28490407 |
|
Status: |
ACTIVE
WITH PARTIAL DIVISION OF CAPITAL |
|
Incorporation
Date: |
26/09/1977 |
|
Register Data |
Register
Section 8 Sheet 120046 |
|
Last Publication in BORME: |
12/08/2015
[Appointments] |
|
Last
Published Account Deposit: |
2014 |
|
Share
Capital: |
2.842.730 |
|
|
|
|
Localization: |
CL.
SEVERO OCHOA, 2 PARQUE TECNOLOGICO DE MADRID - TRES CANTOS - 28760 - MADRID |
|
Telephone
- Fax - Email - Website: |
Telephone.
918 870 600 / 918 070 300 Email. es-ci@gsk.com Website. www.gsk.es |
|
|
|
|
Activity: |
|
|
NACE: |
2120
- Manufacture of pharmaceutical preparations |
|
Registered
Trademarks: |
|
|
Audited
/ Opinion: |
Si
/ |
|
Tenders
and Awards: |
100
for a total cost of NaN |
|
Subsidies: |
4
for a total cost of 74409 |
|
Quality
Certificate: |
No |
|
|
|
|
Payment
Behaviour: |
According
to the agreed terms |
|
Prospects: |
Consolidation |
|
Industry
situation: |
Maturity |
|
|
|
|
Defaults, Legal Claims and
Insolvency Proceedings : |
|
|
|
|
|
|
|
Number |
Amount
(€) |
Most
Recent Entry |
|
Insolvency
Proceedings, Bankruptcy and Suspension of Payments |
|
Unpublished |
--- |
--- |
|
Defaults
on debt with Financial Institutions and Large Companies |
|
None |
--- |
--- |
|
Judicial
Claims (Notices, Executive Proceedings, Attachments, Auctions, Bad Debt) |
|
None |
0 |
--- |
|
Proceedings
heard by the Civil Court |
|
Unpublished |
0 |
--- |
|
Proceedings
heard by the Labour Court |
|
Unpublished |
0 |
--- |
|
|
|
Partners: |
|
|
|
GLAXOSMITHKLINE
CONSUMER HEALTHCARE OVERSEAS |
100
% |
|
|
Shares: |
0 |
|
|
Other
Links: |
28 |
|
|
No.
of Active Corporate Bodies: |
|
|
|
Ratios |
2014 |
2013 |
Change |
|
|
|
|
|
Guarantees: |
|
|
Properties
Registered: |
Company
NO, Administrator NO |
|
Financing
/ Guarantee Sources : |
Sources
NO, Guarantees YES |
|
|
|
|
INVESTIGATION
SUMMARY |
|
|
It
is a corporation that was established many years ago, which gives it sufficient
experience in the sector of activities it carries out and it has good
reputation amongst consulted references. Though its invoicing has decreased
with a percentage of 6,28 % in 2014 in comparison to the previous year. It
presents a positive Working Fund, which enables the company to comply with
its short term payment obligations. |
|
|
Enquiry Details |
|
|
Business address regime: |
Property |
Identification
|
|
|
Social Denomination: |
SMITHKLINE BEECHAM SA |
|
NIF / Fiscal code: |
A28490407 |
|
Corporate Status: |
ACTIVE WITH PARTIAL DIVISION OF CAPITAL |
|
Start of activity: |
1977 |
|
Registered Office: |
CL. SEVERO OCHOA, 2 PARQUE TECNOLOGICO DE MADRID |
|
Locality: |
TRES CANTOS |
|
Province: |
MADRID |
|
Postal Code: |
28760 |
|
Telephone: |
918 870 600 / 918 070 300 |
|
Fax: |
918 070 310 |
|
Website: |
www.gsk.es |
|
Email: |
|
Activity
|
|
|
NACE: |
2120 |
|
Legal Form: |
THE REALIZATION OF ALL KINDS OF LICIT COMMERCIAL AND INDUSTRIAL ACTIVITIES RELATED TO THE PURCHASE AND SALE, MANUFACTURE, IMPORTATION, EXPORTATION AND DISTRIBUTION OF PHARMACEUTICAL PRODUCTS. |
|
Additional Information: |
It is dedicated to the manufacture and commercialization of pharmaceutical specialties. |
|
Additional Address: |
CL. SEVERO OCHOA, 2 PARQUE TECNOLOGICO DE MADRID 28760 TRES CANTOS ( MADRID ), central offices. CRTA. AJALVIR, KM 2,500 28806 ALCALA DE HENARES ( MADRID ), registered office, production center. |
|
Import / export: |
IMPORTS / EXPORTS |
|
Future Perspective: |
Consolidation |
|
Industry situation: |
Maturity |
Chronological
Summary
|
|||
|
|
|
|
|
|
|
Year |
Act |
|
|
|
1990 |
Accounts deposit (year 1989) Appointments/ Re-elections (6) Cessations/ Resignations/ Reversals (2) Change of Social address (1) |
|
|
|
1991 |
Accounts deposit (year 1990) Appointments/ Re-elections (11) Cessations/ Resignations/ Reversals (2) |
|
|
|
1992 |
Accounts deposit (year 1991) Appointments/ Re-elections (2) Cessations/ Resignations/ Reversals (2) Other Concepts/ Events (1) |
|
|
|
1993 |
Appointments/ Re-elections (8) Cessations/ Resignations/ Reversals (2) Change of Social Denomination (1) |
|
|
|
1994 |
Accounts deposit (year 1992, 1993) Adaptation to Law (1) Appointments/ Re-elections (9) Cessations/ Resignations/ Reversals (5) Change of Social Purpose (1) Other Concepts/ Events (1) Statutory Modifications (1) |
|
|
|
1995 |
Accounts deposit (year 1994) Appointments/ Re-elections (2) Cessations/ Resignations/ Reversals (2) |
|
|
|
1996 |
Accounts deposit (year 1995) Appointments/ Re-elections (8) Cessations/ Resignations/ Reversals (1) Other Concepts/ Events (2) |
|
|
|
1997 |
Accounts deposit (year 1996) Appointments/ Re-elections (12) Cessations/ Resignations/ Reversals (3) Change of Social Purpose (3) Take-over Merger (3) |
|
|
|
1998 |
Accounts deposit (year 1997) Appointments/ Re-elections (2) Cessations/ Resignations/ Reversals (4) Take-over Merger (5) |
|
|
|
1999 |
Accounts deposit (year 1998) Appointments/ Re-elections (6) Cessations/ Resignations/ Reversals (3) |
|
|
|
2000 |
Accounts deposit (year 1999) Appointments/ Re-elections (5) Cessations/ Resignations/ Reversals (2) Other Concepts/ Events (1) |
|
|
|
2001 |
Accounts deposit (year 2000) Appointments/ Re-elections (8) Cessations/ Resignations/ Reversals (5) Change of Social address (1) |
|
|
|
2002 |
Accounts deposit (year 2001) Appointments/ Re-elections (9) Capital Reduction (4) Cessations/ Resignations/ Reversals (6) Change of Social address (1) Declaration of Sole Propietorship (1) Loss of the sole propietorship condition (1) Other Concepts/ Events (3) Partial split (5) |
|
|
|
2003 |
Accounts deposit (year 2002) Appointments/ Re-elections (4) Cessations/ Resignations/ Reversals (3) |
|
|
|
2004 |
Accounts deposit (year 2003) Appointments/ Re-elections (2) Cessations/ Resignations/ Reversals (2) |
|
|
|
2005 |
Accounts deposit (year 2004) Appointments/ Re-elections (1) |
|
|
|
2006 |
Accounts deposit (year 2005) Appointments/ Re-elections (2) Cessations/ Resignations/ Reversals (3) |
|
|
|
2007 |
Appointments/ Re-elections (2) Cessations/ Resignations/ Reversals (2) |
|
|
|
2008 |
Accounts deposit (year 2006, 2007) Appointments/ Re-elections (4) Cessations/ Resignations/ Reversals (3) |
|
|
|
2009 |
Accounts deposit (year 2008) Appointments/ Re-elections (3) Cessations/ Resignations/ Reversals (2) |
|
|
|
2010 |
Accounts deposit (year 2009) Appointments/ Re-elections (3) Cessations/ Resignations/ Reversals (4) |
|
|
|
2011 |
Accounts deposit (year 2010) Appointments/ Re-elections (5) Cessations/ Resignations/ Reversals (2) |
|
|
|
2012 |
Accounts deposit (year 2011) Appointments/ Re-elections (6) Cessations/ Resignations/ Reversals (2) |
|
|
|
2013 |
Accounts deposit (year 2012) Appointments/ Re-elections (5) Cessations/ Resignations/ Reversals (5) |
|
|
|
2014 |
Accounts deposit (year 2013) Appointments/ Re-elections (3) Cessations/ Resignations/ Reversals (2) |
|
|
|
2015 |
Accounts deposit (year 2014) Appointments/ Re-elections (3) Cessations/ Resignations/ Reversals (2) Declaration of Sole Propietorship (1) Loss of the sole propietorship condition (1) Other Concepts/ Events (1) |
|
Main
Historic Changes
|
|||
|
|
|
|
|
|
Concept |
Publication |
Act |
Date |
|
Corporate Purpose Changes: |
LA INVESTIGACION FARMACEUTICA, ELABORACION, FABRICACION, PRODUCCIOON, PREPARACION, ENVASADO, ACONDICIONAMIENTO, PRESENTACION, CONSTRUCCION, DISTRIBUCION, ETC, DE TODA CLASE DE MEDICAMENTOS, ESPECIALIDADES FARMACEUTICAS |
Corporate Purpose Change |
15/02/1994 |
|
Breakdown
of Owners' Equity
|
|
|
Registered Capital: |
2.842.730 |
|
Paid up capital: |
2.842.730 |
|
Updated
Evolution of the Subscribed and Paid-in Capital
|
|||||
|
|
|
|
|
|
|
|
Publishing Date |
Registration Type |
Capital Subscribed |
Paid up capital |
Underwritten result |
Disbursed Result |
|
01/07/2002 |
Capital Reduction |
-9.177.512 |
-9.177.512 |
2.842.730 |
2.842.730 |
|
Active Social Bodies
|
|
|
|
|
|
Post published |
Social Body's Name |
Appointment Date |
Other Positions in this Company |
|
SINGLE PARTNER |
GLAXOSMITHKLINE CONSUMER HEALTHCARE
-OVERSEAS- |
22/04/2015 |
1 |
|
PRESIDENT |
SANAU TORRECILLA ADELA |
17/07/2012 |
13 |
|
MEMBER OF THE BOARD |
SANAU TORRECILLA ADELA |
17/07/2012 |
13 |
|
|
DE LOS MOZOS CUADRADO JOSE ISMAEL |
22/02/2012 |
2 |
|
|
LOPEZ GONZALEZ IŃIGO |
10/08/2011 |
3 |
|
|
BAUMANN RODRIGO BECKER |
11/01/1999 |
3 |
|
NON CONSELLOR SECRETARY |
COLLDEFORS MARTINEZ JOSE MIGUEL |
15/01/2008 |
11 |
|
ACCOUNTS' AUDITOR / HOLDER |
PRICEWATERHOUSECOOPERS AUDITORES SL |
12/12/2014 |
3 |
|
Historical
Social Bodies
|
|
|
|
|
|
Social Body's Name |
Post published |
End Date |
Other Positions in this Company |
|
BAUMANN RODRIGO BECKER |
SOLE CHIEF EXECUTIVE OFFICER |
15/04/1999 |
3 |
|
|
SOLE CHIEF EXECUTIVE OFFICER |
20/03/2000 |
|
|
BAUMANN RUDIGER BECKER |
PRESIDENT |
08/03/2001 |
7 |
|
|
SOLE CHIEF EXECUTIVE OFFICER |
09/03/2001 |
|
|
BUSHELL RICHARD SPENCER |
MEMBER OF THE BOARD |
08/03/2001 |
1 |
|
CAMPOS COLL JOSE |
MEMBER OF THE BOARD |
19/10/1998 |
3 |
|
CASADO GONZALEZ CECILIO |
MEMBER OF THE BOARD |
24/06/1996 |
11 |
|
|
MEMBER OF THE BOARD |
01/02/2001 |
|
|
|
MEMBER OF THE BOARD |
15/06/1993 |
|
|
COBO DELGADO MANUEL |
MEMBER OF THE BOARD |
08/01/1992 |
3 |
|
COHEN THOMAS WILLIAM |
MEMBER OF THE BOARD |
15/12/1999 |
2 |
|
|
MEMBER OF THE BOARD |
22/08/1995 |
|
|
COLAS GIRALDOS JOSE LUIS |
MEMBER OF THE BOARD |
21/10/2002 |
10 |
|
COLLDEFORS MARTINEZ JOSE MIGUEL |
MEMBER OF THE BOARD |
21/10/2002 |
11 |
|
|
NON CONSELLOR SECRETARY |
15/01/2008 |
|
|
DEL VALLE ALVAREZ ELOINA |
MEMBER OF THE BOARD |
15/01/2008 |
3 |
|
|
MEMBER OF THE BOARD |
22/02/2012 |
|
|
DIAZ TEJEIRO GUTIERREZ MAR |
MEMBER OF THE BOARD |
06/05/2004 |
3 |
|
DOUGLAS GREENACRE MARTYN |
MEMBER OF THE BOARD |
04/07/1991 |
1 |
|
GALDON CABRERA CARLOS |
MEMBER OF THE BOARD |
21/10/2002 |
8 |
|
|
CHIEF EXECUTIVE OFFICER |
21/10/2002 |
|
|
|
PRESIDENT |
21/10/2002 |
|
|
GARCIA MALDONADO JOSE TOMAS |
MEMBER OF THE BOARD |
15/06/1993 |
24 |
|
|
MEMBER OF THE BOARD |
22/08/1995 |
|
|
|
SECRETARY |
20/03/2000 |
|
|
|
SECRETARY |
08/03/2001 |
|
|
|
MEMBER OF THE BOARD |
08/03/2001 |
|
|
|
SECRETARY |
24/06/1996 |
|
|
|
SECRETARY |
11/01/1999 |
|
|
|
SECRETARY |
16/06/1997 |
|
|
|
MEMBER OF THE BOARD |
16/06/1997 |
|
|
|
SECRETARY |
03/06/1998 |
|
|
GLAXOSMITHKLINE SA |
SINGLE PARTNER |
22/04/2015 |
1 |
|
GRIST ASHLEY |
MEMBER OF THE BOARD |
21/12/2006 |
2 |
|
HUDSON PHILIP DAVID |
MEMBER OF THE BOARD |
08/03/2001 |
1 |
|
JORDAN STEPHEN THOMAS |
MEMBER OF THE BOARD |
15/09/2004 |
1 |
|
LOCKHART TRACY |
MEMBER OF THE BOARD |
21/12/2006 |
1 |
|
LOPEZ GONZALEZ IŃIGO |
MEMBER OF THE BOARD |
10/08/2011 |
3 |
|
MARSON ANTHONY |
MEMBER OF THE BOARD |
24/09/1990 |
1 |
|
NOGALES VERCELLONE JOSE ROBERTO |
MEMBER OF THE BOARD |
24/11/1992 |
3 |
|
PARIS VICENTE GONZALO |
MEMBER OF THE BOARD |
21/10/2002 |
7 |
|
PETERS COLLIN NICANDRO VALERIO |
MEMBER OF THE BOARD |
15/09/2004 |
1 |
|
PRICE WATERHOUSE COOPERS AUDITORES SL |
ACCOUNTS' AUDITOR / HOLDER |
19/10/2004 |
10 |
|
|
ACCOUNTS' AUDITOR / HOLDER |
29/11/2005 |
|
|
|
ACCOUNTS' AUDITOR / HOLDER |
18/12/2006 |
|
|
|
ACCOUNTS' AUDITOR / HOLDER |
30/11/2011 |
|
|
|
ACCOUNTS' AUDITOR / HOLDER |
17/01/2008 |
|
|
|
ACCOUNTS' AUDITOR / HOLDER |
01/10/2008 |
|
|
|
ACCOUNTS' AUDITOR / HOLDER |
11/11/2009 |
|
|
|
ACCOUNTS' AUDITOR / HOLDER |
19/11/2010 |
|
|
|
ACCOUNTS' AUDITOR / HOLDER |
29/12/2003 |
|
|
|
ACCOUNTS' AUDITOR / HOLDER |
18/10/2012 |
|
|
PRICEWATERHOUSECOOPERS AUDITORES SL |
ACCOUNTS' AUDITOR / HOLDER |
26/12/2013 |
3 |
|
|
ACCOUNTS' AUDITOR / HOLDER |
12/12/2014 |
|
|
RODRIGUEZ ROVIRA EDUARDO |
MEMBER OF THE BOARD |
22/08/1995 |
13 |
|
|
PRESIDENT |
22/08/1995 |
|
|
|
PRESIDENT |
24/06/1996 |
|
|
|
SOLE CHIEF EXECUTIVE OFFICER |
24/06/1996 |
|
|
|
PRESIDENT |
16/06/1997 |
|
|
|
JOINT CHIEF EXECUTIVE OFFICER |
16/06/1997 |
|
|
|
PRESIDENT |
31/03/1998 |
|
|
|
SOLE CHIEF EXECUTIVE OFFICER |
31/03/1998 |
|
|
|
PRESIDENT |
11/01/1999 |
|
|
|
PRESIDENT |
20/03/2000 |
|
|
|
MEMBER OF THE BOARD |
20/03/2000 |
|
|
ROXBURGH STRONG ALAN |
MEMBER OF THE BOARD |
24/09/1990 |
2 |
|
|
PRESIDENT |
24/09/1990 |
|
|
SANAU TORRECILLA ADELA |
MEMBER OF THE BOARD |
17/07/2012 |
13 |
|
|
PRESIDENT |
17/07/2012 |
|
|
|
PRESIDENT |
15/01/2008 |
|
|
|
MEMBER OF THE BOARD |
15/01/2008 |
|
|
SMITHKLINE BEECHAM INTERCREDIT B.V. |
SINGLE PARTNER |
17/10/2002 |
1 |
|
URCELAY ALONSO JAVIER |
MEMBER OF THE BOARD |
04/07/1991 |
2 |
|
WHEELDON CARL |
MEMBER OF THE BOARD |
24/09/1990 |
1 |
Defaults, Legal Claims and Insolvency
Proceedings
|
|
|
|
|
Section enabling assessment of the degree of
compliance of the company queried with its payment obligations. It provides information
on the existence and nature of all stages of Insolvency and Legal Proceedings
published with reference to the Company in the country's various Official
Bulletins and national newspapers, as well Defaults Registered in the main
national credit bureaus (ASNEF Industrial and RAI ).
>
Summary
Chronological summary
|
|
|
Number
of Publications |
Amount
(_) |
Start
date |
End
date |
|
Insolvency
Proceedings, Bankruptcy and Suspension of Payments |
|
Unpublished |
--- |
--- |
--- |
|
Request/Declaration |
|
0 |
--- |
date |
|
|
Proceedings |
|
--- |
--- |
|
--- |
|
Resolution |
|
--- |
--- |
|
--- |
|
Defaults
on debt with Financial Institutions and Large Companies |
Bank
and Commercial Delinquency |
None |
0 |
|
|
|
Status:
Friendly |
|
--- |
|
|
|
|
Status:
Pre-Litigation |
|
--- |
|
|
|
|
Status:
Litigation |
|
--- |
|
|
|
|
Status:
Non-performing |
|
--- |
|
|
|
|
Status:
insolvency proceedings, bankruptcy and suspension of payments |
|
--- |
|
|
|
|
Other
status |
|
--- |
|
|
|
|
Legal
and Administrative Proceedings |
|
Unpublished |
--- |
|
|
|
Notices
of defaults and enforcement |
|
--- |
--- |
|
--- |
|
Seizures |
|
--- |
--- |
|
--- |
|
Auctions |
|
--- |
--- |
|
--- |
|
Declarations
of insolvency and bad debt |
|
--- |
--- |
|
--- |
|
Proceedings
heard by the Civil Court |
|
Unpublished |
--- |
|
|
|
Proceedings
heard by the Labour Court |
|
Unpublished |
--- |
|
|
> Details
> Basis for scoring
|
Positive Factors |
Adverse Factors |
|
No irregular payment performance has been
detected based on information obtained from credit bureaus. The current debt represents a 15.58of the financial
structure. In principle, a decrease in this ratio would indicate an
improvement in the short-term financial situation. SMITHKLINE BEECHAM SA obtains economic
profitability from the necessary investments in the development of its
activity in comparison with its assets. It has financial profitability.. SMITHKLINE
BEECHAM SA obtains financial return as a consequence of an investment in its
own resources which, a priori, might improve its financial and economic
situation. Positive Working CapitalThe Company's Working
Capital quality is significant, i.e. much of the Company financing comes from
its equity. A structure is considered optimal if its liquidity level is
slightly above its debt volume as a result of low idleness levels of its
financial resources involved. |
Limited capacity to generate cash and cash
equivalents through operating income. In principle, a decrease in this ratio
would indicate a worsening in the Company´s financial situation. No Company's subsidiaries or branches are
known. |
The information contained in the latest
annual statements has led to a Scoring review for the company.
Probability
of default
|
|
|
|
|
>
Estimated Probability of Default for the next 12 months: 0.517 %
|
Sector in which comparison is carried out: 212 Manufacture of pharmaceutical
preparations |
|
|
Relative Position:
|
The company's comparative analysis with the rest of
the companies that comprise the sector, shows the company holds a better
position with regard to the probability of non-compliance.
The 87.00% of the companies of the sector
SMITHKLINE BEECHAM SA belongs to show a higher probability of non-compliance.
The probability of the company's
non-compliance with its payment obligations within deadlines estimated by our
qualifications models is 0.517%.
In
the event they fail to comply with the payment, the seriousness of the loss
will depend on factors such as the promptness of the commencement of the
charging management, the existence of executive documents which match the
credit or the existence of guarantees and free debt assets under the name of
the debtor. Therefore, the probability of non-compliance should not be solely
interpreted as the total loss of the owed amount.
LEGAL
CLAIMS
|
|
|
|
|
|
Summary
of Judicial Claims |
|
|
|
|
|
|
|
|
||
|
|
|
No se han publicado |
|
|
|
|
No se han publicado |
|
|
|
|
||
|
|
|
No se han publicado |
|
|
|
|
No se han publicado |
|
|
|
|
No se han publicado |
|
|
|
|
No se han publicado |
|
|
|
|
||
|
|
|
No se han publicado |
|
|
|
|
No se han publicado |
|
|
|
|
||
|
|
|
No se han publicado |
|
Link
List
|
|
|
|
|
|
ABSORBS
TO: |
2 Entities |
|
HAS
IN ITS ADMINISTRATION BOARD TO: |
1 Entities |
|
IS
RELATED WITH: |
23 Entities |
|
SE
ESCINDE PARCIALMENTE EN: |
2 Entities |
|
SHAREHOLDERS: |
1 Entities |
>
Shareholders
|
Relationship |
Entity |
Province |
Shareholding
stake |
|
SHAREHOLDERS |
GLAXOSMITHKLINE
CONSUMER HEALTHCARE OVERSEAS |
|
100 |
>
Other relationships
|
Relationship |
Entity |
Province |
Shareholding
stake |
|
IS
RELATED WITH |
|
| |
|
|
|
|
GLAXOSMITHKLINE
EXPORT, SOCIEDAD ANONIMA, (REINO UNIDO) |
|
|
|
|
GLAXOSMITHKLINE
PANAMA |
|
|
|
|
GLAXOSMITHKLINE
SERVICES |
|
|
|
|
GLAXOSMITHKLINE
TRADING SERVICES |
|
|
|
|
GSK
CONSUMER TRADING SERVICES, SOCIEDAD ANONIMA, DK |
|
|
|
|
GSK
CONSUMER TRADING SERVICES, SOCIEDAD ANONIMA, IT |
|
|
|
|
GSK
CONSUMERTRADING SERVICES, SOCIEDAD ANONIMA, BE |
|
|
|
|
GSK
DUNGARVAN, SOCIEDAD ANONIMA, (IRLANDA) |
|
|
|
|
GSK
SERVICES PLC |
|
|
|
|
GSK
SERVICES UNLIMITED (REINO UNIDO) |
|
|
|
|
GSK
TRADING SERVICES, SOCIEDAD ANONIMA, REINO UNIDO |
|
|
|
|
SMITHKLINE
BEECHAM CONSUMER HEALTHC |
|
|
|
|
SMITHKLINE
BEECHAM CORPORATE CENTER (USA) |
|
|
|
|
GLAXOSMITHKLINE
CONSUMER HEALTHCARE SA |
MADRID |
|
|
|
GLAXO
WELLCOME HOUSE |
|
|
|
|
GLAXOSMITHKLINE
FINANCE PLC |
|
|
|
|
GLAXOSMITHKLINE
IHC, SOCIEDAD ANONIMA, (REINO UNIDO) |
|
|
|
|
GSK
CONSUMER TRADING SERVICES |
|
|
|
|
GSK
CONSUMER TRADING SERVICES, SOCIEDAD ANONIMA, BE |
|
|
|
|
GSK
TRADING SERVICES, SOCIEDAD ANONIMA, BE |
|
|
|
|
STIEFEL
IRELAN, S.A. |
|
|
|
|
NOVARTIS
FARMACEUTICA SA. |
BARCELONA |
|
|
|
NOVARTIS
VACCINES AND DIAGNOSTICS SL |
BARCELONA |
|
|
ABSORBS
TO |
STERLING
HEALTH CORPORATION, S.L. |
MADRID |
|
|
|
ABTEI
ESPAŃA, S.L. |
MADRID |
|
|
SE
ESCINDE PARCIALMENTE EN |
GLAXOSMITHKLINE
INVESTIGACION Y DESARROLLO SL |
MADRID |
|
|
|
GLAXOSMITHKLINE
SA |
MADRID |
|
|
HAS
IN ITS ADMINISTRATION BOARD TO |
MULTIGESTION
IBERIA 2014 SL |
MADRID |
|
|
Turnover
|
|
|
Total Sales 2014 |
39.399.547 |
The
sales data is from the latest available financial statements. Failing that, are
estimates data calculated by statistical methods.
|
Financial
Accounts and Balance Sheets
|
|
|
|
|
Financial
Years Presented
|
Ejercicio |
Tipo
de Cuentas Anuales |
Fecha
Presentacion |
|
2014 |
Normales |
September
2015 |
|
2013 |
Normales |
October
2014 |
|
2012 |
Normales |
July
2013 |
|
2011 |
Normales |
September
2012 |
|
2010 |
Normales |
September
2011 |
|
2009 |
Normales |
September
2010 |
|
2008 |
Normales |
November
2009 |
|
2007 |
Normales |
September
2008 |
|
2006 |
Normales |
January
2008 |
|
2005 |
Normales |
September
2006 |
|
2004 |
Normales |
August
2005 |
|
2003 |
Normales |
August
2004 |
|
2002 |
Normales |
July
2003 |
|
2001 |
Normales |
August
2002 |
|
2000 |
Normales |
August
2001 |
|
1999 |
Normales |
August
2000 |
|
1998 |
Normales |
July
1999 |
|
1997 |
Normales |
November
1998 |
|
1996 |
Normales |
November
1997 |
|
1995 |
Normales |
August
1996 |
|
1994 |
Normales |
November
1995 |
|
1993 |
Normales |
September
1994 |
|
1992 |
Normales |
January
1994 |
|
1991 |
Normales |
September
1992 |
|
1990 |
Normales |
August
1991 |
|
1989 |
Normales |
August
1990 |
The data in the report regarding
the last Company Accounts submitted by the company is taken from the TRADE
REGISTER serving the region in which the company's address is located
31/12/2014
>
Normal format Balance in accordance with the New Accounting Plan 2007
Information corresponding to the
fiscal year 2014 2013 2012 2011 2010 is taken from
information submitted to the TRADE REGISTER. Data corresponding to fiscal years
before 2014 2013 2012 2011 2010 has been compiled
based on the equivalence criteria stipulated in Act JUS/206/2009. Where the
provisions of the Act did not establish relevant equivalence criteria, To view
details on the methodology.
|
|
ORIGINAL |
ORIGINAL |
ORIGINAL |
ORIGINAL |
ORIGINAL |
|
|
Assets |
2014 |
2013 |
2012 |
2011 |
2010 |
|
|
A) NON-CURRENT ASSETS: 11000 |
19.758.890,00 |
17.976.888,00 |
17.829.188,00 |
17.844.543,00 |
17.837.126,00 |
|
|
I. Intangible fixed assets :
11100 |
9.990,00 |
10.466,00 |
8.867,00 |
17.321,00 |
37.174,00 |
|
|
1. Development: 11110 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Concessions: 11120 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Patents, licencing, trade marks
and similar: 11130 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Goodwill: 11140 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
5. IT applications: 11150 |
9.990,00 |
10.466,00 |
8.867,00 |
17.321,00 |
37.174,00 |
|
|
6. Investigation: 11160 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
7. Intellectual property: 11180 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
8. Greenhouse gas emission
allowance: 11190 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
9. Other intangible fixed assets.
: 11170 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
II. Tangible fixed assets : 11200 |
18.590.025,00 |
17.067.544,00 |
17.342.070,00 |
17.574.633,00 |
17.470.769,00 |
|
|
1. Land and buildings: 11210 |
5.693.203,00 |
5.909.469,00 |
5.960.565,00 |
5.625.533,00 |
5.764.255,00 |
|
|
2. Technical installations and
other tangible fixed assets: 11220 |
8.789.537,00 |
9.179.958,00 |
10.286.990,00 |
9.704.487,00 |
10.531.401,00 |
|
|
3. Tangible asset in progress and
advances: 11230 |
4.107.285,00 |
1.978.117,00 |
1.094.515,00 |
2.244.613,00 |
1.175.113,00 |
|
|
III. Real estate investment:
11300 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Land: 11310 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Buildings: 11320 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
IV. Long-term investments in
Group companies and associates : 11400 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Equity instruments: 11410 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Credits to businesses: 11420 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Debt securities: 11430 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Derivatives : 11440 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
5. Other financial assets : 11450 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
6. Other investments: 11460 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
V. Long-term financial
investments: 11500 |
2.345,00 |
2.304,00 |
2.304,00 |
2.304,00 |
2.304,00 |
|
|
1. Equity instruments: 11510 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Credits to third parties :
11520 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Debt securities: 11530 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Derivatives : 11540 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
5. Other financial assets : 11550 |
2.345,00 |
2.304,00 |
2.304,00 |
2.304,00 |
2.304,00 |
|
|
6. Other investments: 11560 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VI. Assets for deferred tax :
11600 |
1.156.530,00 |
896.574,00 |
475.947,00 |
250.285,00 |
326.879,00 |
|
|
VII. Non-current trade debts :
11700 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B) CURRENT ASSETS: 12000 |
22.632.402,00 |
25.536.978,00 |
24.433.584,00 |
22.889.039,00 |
25.651.124,00 |
|
|
I. Non-current assets held for
sale : 12100 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
II. Stocks: 12200 |
6.492.621,00 |
5.462.120,00 |
5.819.389,00 |
4.442.223,00 |
7.538.186,00 |
|
|
1. Commercial: 12210 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Primary material and other
supplies: 12220 |
3.141.275,00 |
2.666.614,00 |
2.511.367,00 |
2.222.328,00 |
2.759.264,00 |
|
|
3. Work in progress: 12230 |
773.124,00 |
640.628,00 |
631.130,00 |
586.244,00 |
1.625.927,00 |
|
|
a) Of long-term production cycle
: 12231 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Of short-term production cycle
: 12232 |
773.124,00 |
640.628,00 |
631.130,00 |
586.244,00 |
1.625.927,00 |
|
|
4. Finished goods: 12240 |
2.319.363,00 |
1.656.622,00 |
2.496.407,00 |
1.564.746,00 |
3.151.122,00 |
|
|
a) Of long-term production cycle
: 12241 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Of short-term production cycle
: 12242 |
2.319.363,00 |
1.656.622,00 |
2.496.407,00 |
1.564.746,00 |
3.151.122,00 |
|
|
5. By-products, residues and
recycled materials: 12250 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
6. Advances to suppliers: 12260 |
258.859,00 |
498.256,00 |
180.485,00 |
68.905,00 |
1.873,00 |
|
|
III. Trade debtors and others
receivable accounts: 12300 |
3.496.051,00 |
5.377.694,00 |
5.990.756,00 |
4.150.715,00 |
4.718.665,00 |
|
|
1. Trade debtors / accounts
receivable: 12310 |
254.341,00 |
234.341,00 |
386.349,00 |
0,00 |
428.503,00 |
|
|
a) Long-term receivables from
sales and services supplied : 12311 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Customers for sales and
provisions of services : 12312 |
254.341,00 |
234.341,00 |
386.349,00 |
0,00 |
428.503,00 |
|
|
2. Customers, Group companies and
associates : 12320 |
3.222.641,00 |
4.319.141,00 |
3.553.892,00 |
2.140.431,00 |
2.627.941,00 |
|
|
3. Other accounts receivable:
12330 |
498,00 |
613.701,00 |
11.388,00 |
354,00 |
0,00 |
|
|
4. Personnel: 12340 |
18.571,00 |
8.819,00 |
2.068,00 |
1.764,00 |
155,00 |
|
|
5. Assets for deferred tax: 12350 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
6. Other debtors, including tax
and social security: 12360 |
0,00 |
201.692,00 |
2.037.059,00 |
2.008.166,00 |
1.662.066,00 |
|
|
7. Called up share capital: 12370 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
IV. Short-term investments in
Group companies and associates: 12400 |
12.239.641,00 |
14.473.793,00 |
12.482.372,00 |
14.197.555,00 |
13.311.063,00 |
|
|
1. Equity instruments: 12410 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Credits to businesses: 12420 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Debt securities: 12430 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Derivatives : 12440 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
5. Other financial assets : 12450 |
12.239.641,00 |
14.473.793,00 |
12.482.372,00 |
14.197.555,00 |
13.311.063,00 |
|
|
6. Other investments: 12460 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
V. Short-term financial
investments : 12500 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Equity instruments: 12510 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Credits to businesses: 12520 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Debt securities: 12530 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Derivatives : 12540 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
5. Other financial assets : 12550 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
6. Other investments: 12560 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VI. Short-term accruals: 12600 |
171.424,00 |
168.446,00 |
140.683,00 |
97.085,00 |
82.707,00 |
|
|
VII. Cash and other equivalent
liquid assets : 12700 |
232.665,00 |
54.925,00 |
384,00 |
1.461,00 |
503,00 |
|
|
1. Treasury: 12710 |
232.665,00 |
54.925,00 |
384,00 |
1.461,00 |
503,00 |
|
|
2. Other equivalent liquid
assets: 12720 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
TOTAL ASSETS (A + B) : 10000 |
42.391.292,00 |
43.513.866,00 |
42.262.772,00 |
40.733.582,00 |
43.488.250,00 |
|
|
|
ORIGINAL |
ORIGINAL |
ORIGINAL |
ORIGINAL |
ORIGINAL |
|
|
Liabilities and Net Worth |
2014 |
2013 |
2012 |
2011 |
2010 |
|
|
A) NET WORTH: 20000 |
35.754.169,00 |
36.566.987,00 |
35.400.050,00 |
34.613.458,00 |
34.423.657,00 |
|
|
A-1) Shareholders' equity: 21000 |
35.754.169,00 |
36.566.987,00 |
35.400.050,00 |
34.613.458,00 |
34.423.657,00 |
|
|
I. Capital: 21100 |
2.842.730,00 |
2.842.730,00 |
2.842.730,00 |
2.842.730,00 |
2.842.730,00 |
|
|
1. Registered capital : 21110 |
2.842.730,00 |
2.842.730,00 |
2.842.730,00 |
2.842.730,00 |
2.842.730,00 |
|
|
2. (Uncalled capital): 21120 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
II. Share premium: 21200 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
III. Reserves: 21300 |
32.029.793,00 |
32.029.793,00 |
31.760.462,00 |
31.580.927,00 |
31.311.189,00 |
|
|
1. Legal and statutory: 21310 |
568.546,00 |
568.546,00 |
568.546,00 |
568.546,00 |
568.546,00 |
|
|
2. Other reserves: 21320 |
31.461.247,00 |
31.461.247,00 |
31.191.916,00 |
31.012.381,00 |
30.742.643,00 |
|
|
3. Revaluation reserves: 21330 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
IV. (Common stock equity): 21400 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
V. Results from previous periods:
21500 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Brought forward: 21510 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. (Negative results from
previous periods): 21520 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VI. Other shareholders'
contributions: 21600 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VII. Result of the period: 21700 |
881.646,00 |
1.694.464,00 |
796.858,00 |
189.801,00 |
269.738,00 |
|
|
VIII. (Interim dividend): 21800 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
IX. Other net worth instruments:
21900 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A-2) Adjustments due to changes in
value: 22000 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
I. Financial assets held for
sale: 22100 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
II. Hedge operations: 22200 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
III. Linked non-current assets
and liabilities held for sale : 22300 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
IV. Exchange rate difference:
22400 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
V. Other: 22500 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A-3) Received subsidies,
donations and legacies: 23000 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B) NON-CURRENT LIABILITIES: 31000 |
34.666,00 |
57.931,00 |
62.675,00 |
64.522,00 |
67.148,00 |
|
|
I. Long-term provisions: 31100 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Long-term employee benefits
liability: 31110 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Environmental actions: 31120 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Restructuring provisions:
31130 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Other provisions: 31140 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
II Long-term creditors: 31200 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Liabilities and other
securities: 31210 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Amounts owed to credit
institutions: 31220 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Creditors from financial
leasing: 31230 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Derivatives : 31240 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
5. Other financial liabilities :
31250 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
III. Long-term debts with Group
companies and associates: 31300 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
IV. Liabilities for deferred tax:
31400 |
34.666,00 |
57.931,00 |
62.675,00 |
64.522,00 |
67.148,00 |
|
|
V. Long-term accruals: 31500 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VI. Non-current trade creditors :
31600 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VII. Special long-term debts : 31700 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
C) CURRENT LIABILITIES : 32000 |
6.602.457,00 |
6.888.948,00 |
6.800.047,00 |
6.055.602,00 |
8.997.445,00 |
|
|
I. Liabilities linked to
non-current assets held for sale: 32100 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
II. Short-term provisions: 32200 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Provisions from greenhouse gas
emission allowance: 32210 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Other provisions: 32220 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
III. Short-term creditors : 32300 |
808.180,00 |
337.337,00 |
528.149,00 |
333.718,00 |
764.080,00 |
|
|
1. Liabilities and other
securities: 32310 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Amounts owed to credit
institutions: 32320 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Creditors from financial
leasing: 32330 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Derivatives : 32340 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
5. Other financial liabilities :
32350 |
808.180,00 |
337.337,00 |
528.149,00 |
333.718,00 |
764.080,00 |
|
|
IV. Short-term debts with Group
companies and associates: 32400 |
829.219,00 |
895.761,00 |
380.432,00 |
118.659,00 |
111.556,00 |
|
|
V. Trade creditors and other
accounts payable: 32500 |
4.965.058,00 |
5.655.850,00 |
5.891.466,00 |
5.603.225,00 |
8.121.809,00 |
|
|
1. Suppliers: 32510 |
1.657.469,00 |
2.054.760,00 |
2.636.432,00 |
1.637.870,00 |
3.116.491,00 |
|
|
a) Long-term debts : 32511 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Short-term debts : 32512 |
1.657.469,00 |
2.054.760,00 |
2.636.432,00 |
1.637.870,00 |
3.116.491,00 |
|
|
2. Suppliers, Group companies and
associates: 32520 |
265.423,00 |
70.405,00 |
361.897,00 |
606.714,00 |
1.657.728,00 |
|
|
3. Other creditors: 32530 |
1.835.239,00 |
2.488.528,00 |
2.009.831,00 |
2.238.298,00 |
1.982.626,00 |
|
|
4. Personnel (remuneration due):
32540 |
811.996,00 |
672.171,00 |
531.061,00 |
765.518,00 |
975.985,00 |
|
|
5. Liabilities for current tax:
32550 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
6. Other accounts payable to
Public Administrations.: 32560 |
394.931,00 |
369.986,00 |
352.245,00 |
354.825,00 |
388.979,00 |
|
|
7. Advances from clients: 32570 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VI. Short-term accruals: 32600 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VII. Special short-term debts :
32700 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
TOTAL NET WORTH AND LIABILITIES
(A + B + C) : 30000 |
42.391.292,00 |
43.513.866,00 |
42.262.772,00 |
40.733.582,00 |
43.488.250,00 |
|
|
|
ORIGINAL |
ORIGINAL |
ORIGINAL |
ORIGINAL |
ORIGINAL |
|
|
Profit and Loss |
2014 |
2013 |
2012 |
2011 |
2010 |
|
|
1. Net turnover: 40100 |
39.399.547,00 |
42.040.801,00 |
38.350.618,00 |
53.411.595,00 |
51.791.118,00 |
|
|
a) Sales: 40110 |
37.457.839,00 |
41.759.094,00 |
37.830.526,00 |
53.199.111,00 |
51.696.939,00 |
|
|
b) Rendering of services: 40120 |
1.941.708,00 |
281.707,00 |
520.092,00 |
212.484,00 |
94.179,00 |
|
|
c) Income of financial nature of
holding companies: 40130 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Changes in stocks of finished goods
and work in progress: 40200 |
795.237,00 |
-830.288,00 |
976.547,00 |
-2.626.058,00 |
-2.482.073,00 |
|
|
3. Works carried out by the
company for its assets: 40300 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Supplies : 40400 |
-20.966.909,00 |
-22.716.216,00 |
-22.463.914,00 |
-33.942.241,00 |
-30.511.507,00 |
|
|
a) Stock consumption: 40410 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Consumption of raw materials
and miscellaneous consumable ones: 40420 |
-20.949.417,00 |
-22.710.016,00 |
-22.752.953,00 |
-33.405.304,00 |
-28.332.294,00 |
|
|
c) Works carried out by other
companies: 40430 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
d) Impairment of stock, primary
material and other supplies: 40440 |
-17.492,00 |
-6.200,00 |
289.039,00 |
-536.937,00 |
-2.179.213,00 |
|
|
5. Other operating income: 40500 |
1.105,00 |
19.893,00 |
40.426,00 |
28.387,00 |
5.761,00 |
|
|
a) Auxiliary income and other
from current management: 40510 |
0,00 |
0,00 |
0,00 |
300,00 |
969,00 |
|
|
b) Operation subsidies included
in the Period's result: 40520 |
1.105,00 |
19.893,00 |
40.426,00 |
28.087,00 |
4.792,00 |
|
|
6. Personnel costs: 40600 |
-10.583.658,00 |
-9.271.653,00 |
-8.737.269,00 |
-9.626.286,00 |
-10.519.833,00 |
|
|
a) Wages, salaries et al.: 40610 |
-7.539.859,00 |
-6.716.843,00 |
-6.309.523,00 |
-7.127.713,00 |
-7.917.202,00 |
|
|
b) Social security costs: 40620 |
-3.043.799,00 |
-2.554.810,00 |
-2.427.746,00 |
-2.498.573,00 |
-2.602.631,00 |
|
|
c) Provisions : 40630 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
7. Other operating costs: 40700 |
-4.966.316,00 |
-4.692.595,00 |
-4.799.225,00 |
-4.621.912,00 |
-5.396.386,00 |
|
|
a) External services: 40710 |
-4.844.922,00 |
-4.551.663,00 |
-4.682.975,00 |
-4.499.010,00 |
-5.280.923,00 |
|
|
b) Taxes: 40720 |
-121.394,00 |
-140.932,00 |
-116.250,00 |
-122.902,00 |
-115.463,00 |
|
|
c) Losses, impairments and variation
in provisions from trade operations : 40730 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
d) Other current management
expenditure : 40740 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
e) Expenses due to greenhouse gas
emissions: 40750 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
8. Amortisation of fixed assets:
40800 |
-2.273.592,00 |
-2.350.609,00 |
-2.380.704,00 |
-2.439.498,00 |
-2.460.426,00 |
|
|
9. Allocation of subsidies of
non-financial fixed assets and other: 40900 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
10. Excess provisions : 41000 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
11. Impairment and result of
transfers of fixed assets: 41100 |
-30.638,00 |
-50.396,00 |
-19.643,00 |
-4.829,00 |
-14.644,00 |
|
|
a) Impairment and losses : 41110 |
0,00 |
0,00 |
0,00 |
0,00 |
19.870,00 |
|
|
b) Results for transfers and
other : 41120 |
-30.638,00 |
-50.396,00 |
-19.643,00 |
-4.829,00 |
-34.514,00 |
|
|
c) Impairment and profit due to disposals
of assets of holding companies: 41130 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
12. Negative difference in
combined businesses: 41200 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
13. Other results : 41300 |
99.509,00 |
2.132,00 |
-11.013,00 |
215.210,00 |
58.394,00 |
|
|
A.1) OPERATING INCOME (1 + 2 + 3
+ 4 + 5 + 6 + 7 + 8 + 9 + 10 + 11 + 12 + 13) : 49100 |
1.474.285,00 |
2.151.069,00 |
955.823,00 |
394.368,00 |
470.404,00 |
|
|
14. Financial income : 41400 |
12.947,00 |
1.897,00 |
0,00 |
92,00 |
482,00 |
|
|
a) Of shares in equity
instruments : 41410 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
a 1) In Group companies and
associates: 41411 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
a 2) In third parties: 41412 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) From negotiable securities and
other financial instruments : 41420 |
12.947,00 |
1.897,00 |
0,00 |
92,00 |
482,00 |
|
|
b 1) From Group companies and
associates : 41421 |
12.947,00 |
1.871,00 |
0,00 |
0,00 |
0,00 |
|
|
b 2) From third parties : 41422 |
0,00 |
26,00 |
0,00 |
92,00 |
482,00 |
|
|
c) Allocation of financial
subsidies, donations and legacies : 41430 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
15. Financial expenditure: 41500 |
-198,00 |
0,00 |
-5.311,00 |
0,00 |
0,00 |
|
|
a) Amounts owed to Group
companies and associates : 41510 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) For debts with third parties :
41520 |
-198,00 |
0,00 |
-5.311,00 |
0,00 |
0,00 |
|
|
c) Stock renewal : 41530 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
16. Changes in fair value of
financial instruments : 41600 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
a) Trading book and other : 41610 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Allocation of financial assets
held for sale to the result for the period: 41620 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
17. Exchange rate differences :
41700 |
-37.912,00 |
10.353,00 |
-10.973,00 |
27.840,00 |
-7.374,00 |
|
|
18. Impairment and result for
transfers of financial instruments: 41800 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
a) Impairment and losses : 41810 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Results for transfers and
other : 41820 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
19. Other financial income and
expenditure: 42100 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
a) Incorporation of financial
expenditure to assets: 42110 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Financial income from
arrangement with creditors: 42120 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
c) Other income and expenditure:
42130 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.2) FINANCIAL REVENUE (14+15+16+17+18+19)
: 49200 |
-25.163,00 |
12.250,00 |
-16.284,00 |
27.932,00 |
-6.892,00 |
|
|
A.3) NET RESULT BEFORE TAXES
(A.1+A.2) : 49300 |
1.449.122,00 |
2.163.319,00 |
939.539,00 |
422.300,00 |
463.512,00 |
|
|
20. Income taxes: 41900 |
-567.476,00 |
-468.855,00 |
-142.681,00 |
-232.499,00 |
-193.774,00 |
|
|
A.4) PROFIT AFTER TAXES (A.3+20)
: 49400 |
881.646,00 |
1.694.464,00 |
796.858,00 |
189.801,00 |
269.738,00 |
|
|
21. Result of the year coming
from interrupted operations : 42000 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.5) RESULT OF THE PERIOD
(A.4+21) : 49500 |
881.646,00 |
1.694.464,00 |
796.858,00 |
189.801,00 |
269.738,00 |
|
> Normal Balance Sheet under the rules of the
1990 General Accounting Plan (repealed since 1st January of 2008)
Information
corresponding to the fiscal year
2014 2013 2012 2011 2010 has been compiled based on
the equivalence criteria stipulated in Act JUS/206/2009. Where the provisions
of the Act did not establish relevant equivalence criteria. To view details on
the methodology 2014 2013 2012 2011 2010 is taken
from information submitted to the TRADE REGISTER.
|
|
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
|
|
ASSETS |
2014 |
2013 |
2012 |
2011 |
2010 |
|
|
A) SHAREHOLDERS (PARTNERS) BY
UNCALLED SUSCRIBED CAPITAL: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B) FIXED ASSETS: |
18.602.360,00 |
17.080.314,00 |
17.353.241,00 |
17.594.258,00 |
17.510.247,00 |
|
|
I. Formation expenses: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
II. Intangible fixed assets: |
9.990,00 |
10.466,00 |
8.867,00 |
17.321,00 |
37.174,00 |
|
|
1. Research and development
costs: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Concessions, patents,
licences, trademarks et al.: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Goodwill: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Key money paid for premises: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
5. Software: |
9.990,00 |
10.466,00 |
8.867,00 |
17.321,00 |
37.174,00 |
|
|
6. Assets under capital leases: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
7. Payments on account: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
8. Provisions: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
9. Accumulated depreciation: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
III. Tangible fixed assets: |
18.590.025,00 |
17.067.544,00 |
17.342.070,00 |
17.574.633,00 |
17.470.769,00 |
|
|
1. Land and construction: |
5.693.203,00 |
5.909.469,00 |
5.960.565,00 |
5.625.533,00 |
5.764.255,00 |
|
|
2. Technical installations and
machinery: |
4.934.825,00 |
5.154.024,00 |
5.775.559,00 |
5.448.517,00 |
5.912.782,00 |
|
|
3. Other installations, tools and
furniture: |
3.510.183,00 |
3.666.101,00 |
4.108.204,00 |
3.875.576,00 |
4.205.812,00 |
|
|
4. Payments on account and
tangible fixed assets under construction: |
4.107.285,00 |
1.978.117,00 |
1.094.515,00 |
2.244.613,00 |
1.175.113,00 |
|
|
5. Other tangible assets: |
344.530,00 |
359.833,00 |
403.226,00 |
380.393,00 |
412.807,00 |
|
|
6. Provisions: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
7. Accumulated depreciation: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
IV. Financial investments: |
2.345,00 |
2.304,00 |
2.304,00 |
2.304,00 |
2.304,00 |
|
|
1. Equity investments in group
companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Receivables from group
companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Equity investment in
associated companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Credits to associated
companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
5. Long-term securities
portfolio: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
6. Other receivables: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
7. Long term guarantees and
deposits: |
2.345,00 |
2.304,00 |
2.304,00 |
2.304,00 |
2.304,00 |
|
|
8. Provisions: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
9. Long-term receivables from
public bodies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
V. Own shares: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VI. Long-term trade receivables: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
C) Deferred expenses: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
D) CURRENT ASSETS: |
23.788.932,00 |
26.433.552,00 |
24.909.531,00 |
23.139.324,00 |
25.978.003,00 |
|
|
I. Called-up share capital (not
paid): |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
II. Stocks: |
6.492.621,00 |
5.462.120,00 |
5.819.389,00 |
4.442.223,00 |
7.538.186,00 |
|
|
1. Goods for resale: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Raw materials and other
consumables: |
3.141.275,00 |
2.666.614,00 |
2.511.367,00 |
2.222.328,00 |
2.759.264,00 |
|
|
3. Goods in process and
semifinished ones: |
773.124,00 |
640.628,00 |
631.130,00 |
586.244,00 |
1.625.927,00 |
|
|
4. Finished products: |
2.319.363,00 |
1.656.622,00 |
2.496.407,00 |
1.564.746,00 |
3.151.122,00 |
|
|
5. Byproducts, scrap and
recovered materials: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
6. Payments on account: |
258.859,00 |
498.256,00 |
180.485,00 |
68.905,00 |
1.873,00 |
|
|
7. Provisions: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
III. Debtors: |
4.652.581,00 |
6.274.268,00 |
6.466.703,00 |
4.401.000,00 |
5.045.544,00 |
|
|
1. Trade debtors / accounts
receivable: |
254.341,00 |
234.341,00 |
386.349,00 |
0,00 |
428.503,00 |
|
|
2. Accounts receivable, Group
companies: |
3.222.641,00 |
4.319.141,00 |
3.553.892,00 |
2.140.431,00 |
2.627.941,00 |
|
|
3. Accounts receivable,
associated companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Other debtors: |
498,00 |
613.701,00 |
11.388,00 |
354,00 |
0,00 |
|
|
5. Staff: |
18.571,00 |
8.819,00 |
2.068,00 |
1.764,00 |
155,00 |
|
|
6. Public bodies: |
1.156.530,00 |
1.098.266,00 |
2.513.006,00 |
2.258.451,00 |
1.988.945,00 |
|
|
7. Provisions: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
IV. Short-term investments: |
12.239.641,00 |
14.473.793,00 |
12.482.372,00 |
14.197.555,00 |
13.311.063,00 |
|
|
1. Equity investments in group
companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Receivables from group
companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Equity investment in
associated companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Credits to associated
companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
5. Short term securities
portfolio: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
6. Other receivables: |
12.239.641,00 |
14.473.793,00 |
12.482.372,00 |
14.197.555,00 |
13.311.063,00 |
|
|
7. Shor term guarantees and
deposits: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
8. Provisions: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
V. Short-term treasury shares: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VI. Cash at bank and in hand: |
232.665,00 |
54.925,00 |
384,00 |
1.461,00 |
503,00 |
|
|
VII. Prepayments and accrued
income: |
171.424,00 |
168.446,00 |
140.683,00 |
97.085,00 |
82.707,00 |
|
|
GENERAL TOTAL (A + B + C + D): |
42.391.292,00 |
43.513.866,00 |
42.262.772,00 |
40.733.582,00 |
43.488.250,00 |
|
MERCANTILE REGISTRY.
|
|
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
|
|
LIABILITIES |
2014 |
2013 |
2012 |
2011 |
2010 |
|
|
A) EQUITY: |
35.754.169,00 |
36.566.987,00 |
35.400.050,00 |
34.613.458,00 |
34.423.657,00 |
|
|
I. Subscribed capital: |
2.842.730,00 |
2.842.730,00 |
2.842.730,00 |
2.842.730,00 |
2.842.730,00 |
|
|
II. Share premium: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
III. Revaluation reserves: |
1.837.222,00 |
1.837.222,00 |
1.821.494,00 |
1.811.010,00 |
1.795.258,00 |
|
|
IV. Reserves: |
30.192.571,00 |
30.192.571,00 |
29.938.968,00 |
29.769.917,00 |
29.515.931,00 |
|
|
1. Legal reserve: |
568.546,00 |
568.546,00 |
568.546,00 |
568.546,00 |
568.546,00 |
|
|
2. Reserves for own shares: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Reserves for shares of the
controlling company: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Statutory reserves: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
5. Miscellaneous reserves: |
29.623.967,00 |
29.623.967,00 |
29.370.364,00 |
29.201.314,00 |
28.947.328,00 |
|
|
Differences due to capital
adjustement to euros: |
58,00 |
58,00 |
58,00 |
57,00 |
57,00 |
|
|
V. Profit or loss brought
forward: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Retained earnings: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Prior year losses: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Partners' contributions
so as to compensate losses: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VI. Profit or loss for the
financial year: |
881.646,00 |
1.694.464,00 |
796.858,00 |
189.801,00 |
269.738,00 |
|
|
VII. Interim dividend paid: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VIII. Own shares for capital
reduction: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B) Deferred income: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Capital grants: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Unrealised exchange gains: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Other deferred income: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Public revenues to distribute
in several financial years: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
C) PROVISIONS FOR LIABILITIES AND
CHARGES: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Provisions for pension fund
and other similar obligations: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Provisions for taxes: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Other provisions: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Reversion fund: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
D) LONG TERM LIABILITIES: |
34.666,00 |
57.931,00 |
62.675,00 |
64.522,00 |
67.148,00 |
|
|
I. Issued debentures and other
marketable securities: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Non-convertible debentures: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Convertible debentures: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Other debt securities: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
II. Amounts owed to credit
institutions: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Loans and other liabilities: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Long-term liabilities from
capital leases: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
III. Debts with companies of the
group and affiliated ones: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Amounts owed to group
companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Amounts owed to associated
companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
IV. Other creditors: |
34.666,00 |
57.931,00 |
62.675,00 |
64.522,00 |
67.148,00 |
|
|
1. Long-term bills of exchange
payable: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Other creditors: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Long term guarantees and
deposits received: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Long term payables to public
bodies: |
34.666,00 |
57.931,00 |
62.675,00 |
64.522,00 |
67.148,00 |
|
|
V. Unpaid portion of equity
investment: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Group companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Associated companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Third parties: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VI. Long term trade creditors: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
E) SHORT TERM CREDITORS: |
6.602.457,00 |
6.888.948,00 |
6.800.047,00 |
6.055.602,00 |
8.997.445,00 |
|
|
I. Issued debentures and other
marketable securities: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Non-convertible debentures: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Convertible debentures: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Other debt securities: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Accrued interest on debentures
and other debt securities: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
II. Amounts owed to credit institutions: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
1. Loans and other liabilities: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Accrued interest on
liabilities with credit institutions: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Short-term liabilities from
capital leases: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
III. Short-term amounts owed to
group and associated companies: |
1.094.642,00 |
966.166,00 |
742.329,00 |
725.373,00 |
1.769.284,00 |
|
|
1. Amounts owed to group
companies: |
1.094.642,00 |
966.166,00 |
742.329,00 |
725.373,00 |
1.769.284,00 |
|
|
2. Amounts owed to associated
companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
IV. Trade creditors: |
3.492.708,00 |
4.543.288,00 |
4.646.263,00 |
3.876.168,00 |
5.099.117,00 |
|
|
1. Advanced payments from
customers: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
2. Amounts owed for purchases of
goods or services: |
3.492.708,00 |
4.543.288,00 |
4.646.263,00 |
3.876.168,00 |
5.099.117,00 |
|
|
3. Debts represented by notes
payable: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
V. Other creditors: |
2.015.107,00 |
1.379.494,00 |
1.411.455,00 |
1.454.061,00 |
2.129.044,00 |
|
|
1. Public bodies: |
394.931,00 |
369.986,00 |
352.245,00 |
354.825,00 |
388.979,00 |
|
|
2. Bills of exchange payable: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Miscellaneous debts: |
808.180,00 |
337.337,00 |
528.149,00 |
333.718,00 |
764.080,00 |
|
|
4. Wages and salaries payable: |
811.996,00 |
672.171,00 |
531.061,00 |
765.518,00 |
975.985,00 |
|
|
5. Guarantees and deposits
received at short term: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VI. Provisions: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VII. Prepayments and accrued
income: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
F) SHORT-TERM PROVISIONS FOR
LIABILITIES AND CHARGES: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
GENERAL TOTAL (A + B + C + D + E
+ F): |
42.391.292,00 |
43.513.866,00 |
42.262.772,00 |
40.733.582,00 |
43.488.250,00 |
|
MERCANTILE REGISTRY.
|
|
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
|
|
DEBIT |
2014 |
2013 |
2012 |
2011 |
2010 |
|
|
A) CHARGES (A.1 to A.15): |
39.426.699,00 |
40.380.612,00 |
38.570.733,00 |
53.493.323,00 |
51.586.017,00 |
|
|
A.1. Stock reduction of both
manufactured goods and the ones in process: |
0,00 |
830.288,00 |
0,00 |
2.626.058,00 |
2.482.073,00 |
|
|
A.2. Supplies: |
20.949.417,00 |
22.710.016,00 |
22.752.953,00 |
33.405.304,00 |
28.332.294,00 |
|
|
a) Stock consumption: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Consumption of raw materials
and miscellaneous consumable ones: |
20.949.417,00 |
22.710.016,00 |
22.752.953,00 |
33.405.304,00 |
28.332.294,00 |
|
|
c) Miscellaneous external
expenditure: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.3. Staff costs: |
10.583.658,00 |
9.271.653,00 |
8.737.269,00 |
9.626.286,00 |
10.519.833,00 |
|
|
a) Wages, salaries et al.: |
7.539.859,00 |
6.716.843,00 |
6.309.523,00 |
7.127.713,00 |
7.917.202,00 |
|
|
b) Social security costs: |
3.043.799,00 |
2.554.810,00 |
2.427.746,00 |
2.498.573,00 |
2.602.631,00 |
|
|
A.4. Depreciation expense: |
2.273.592,00 |
2.350.609,00 |
2.380.704,00 |
2.439.498,00 |
2.460.426,00 |
|
|
A.5. Variation of trade
provisions and losses of unrecovered receivables: |
17.492,00 |
6.200,00 |
-289.039,00 |
536.937,00 |
2.179.213,00 |
|
|
a) Stock provision variation: |
17.492,00 |
6.200,00 |
-289.039,00 |
536.937,00 |
2.179.213,00 |
|
|
b) Variation in provision and bad
debt losses: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
c) Variation of other trade
provisions: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.6. Other operating charges: |
4.966.316,00 |
4.692.595,00 |
4.799.225,00 |
4.621.912,00 |
5.396.386,00 |
|
|
a) External services: |
4.844.922,00 |
4.551.663,00 |
4.682.975,00 |
4.499.010,00 |
5.280.923,00 |
|
|
b) Taxes: |
121.394,00 |
140.932,00 |
116.250,00 |
122.902,00 |
115.463,00 |
|
|
c) Other operating expenses: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
d) Allocation to revision fund: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.I. OPERATING BENEFITS
(B.1+B.2+B.3+B.4-A.1-A.2-A.3-A.4-A.5-A.6): |
1.405.414,00 |
2.199.333,00 |
986.479,00 |
183.987,00 |
426.654,00 |
|
|
A.7. Financial and similar
charges: |
198,00 |
0,00 |
5.311,00 |
0,00 |
0,00 |
|
|
a) Due to liabilities with
companies of the group: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Due to liabilities with
associated companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
c) Due to other debts.: |
198,00 |
0,00 |
5.311,00 |
0,00 |
0,00 |
|
|
d) Losses from financial
investments: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.8. Changes in financial
investment provisions: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.9. Exchange losses: |
37.912,00 |
0,00 |
10.973,00 |
0,00 |
7.374,00 |
|
|
A.II. NET FINANCIAL INCOME
(B.5+B.6+B.7+B.8-A.7-A.8-A.9): |
0,00 |
12.250,00 |
0,00 |
27.932,00 |
0,00 |
|
|
A.III. PROFIT FROM ORDINARY
ACTIVITIES (A.I+A.II-B.I-B.II): |
1.380.251,00 |
2.211.583,00 |
970.195,00 |
211.919,00 |
419.762,00 |
|
|
A.10. Changes in provisions for
intangible, tangible and securities portfolio: |
0,00 |
0,00 |
0,00 |
0,00 |
-19.870,00 |
|
|
A.11. Losses from tangible and
intangible fixed assets and securities portfolio: |
30.638,00 |
50.396,00 |
19.643,00 |
4.829,00 |
34.514,00 |
|
|
A.12. Losses from transactions
with own shares and debentures: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.13. Extraordinary expenses: |
0,00 |
0,00 |
11.013,00 |
0,00 |
0,00 |
|
|
A.14. Expenses and losses of
former financial years: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.IV. EXTRAORDINARY PROFIT
(B.9+B.10+B.11+B.12+B.13-A.10-A.11-A.12-A.13-A.14): |
68.871,00 |
0,00 |
0,00 |
210.381,00 |
43.750,00 |
|
|
A.V. PROFIT BEFORE TAXES
(A.III+A.IV-B.III-B.IV): |
1.449.122,00 |
2.163.319,00 |
939.539,00 |
422.300,00 |
463.512,00 |
|
|
A.15. Corporation tax: |
567.476,00 |
468.855,00 |
142.681,00 |
232.499,00 |
193.774,00 |
|
|
A.16. Miscellaneous taxes: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.VI. FINANCIAL YEAR RESULTS
(PROFIT) (A.V-A.15-A.16): |
881.646,00 |
1.694.464,00 |
796.858,00 |
189.801,00 |
269.738,00 |
|
MERCANTILE REGISTRY.
|
|
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
|
|
CREDIT |
2014 |
2013 |
2012 |
2011 |
2010 |
|
|
B) INCOME ( B.1 to B.13): |
40.308.345,00 |
42.075.076,00 |
39.367.591,00 |
53.683.124,00 |
51.855.755,00 |
|
|
B.1. Net total sales: |
39.399.547,00 |
42.040.801,00 |
38.350.618,00 |
53.411.595,00 |
51.791.118,00 |
|
|
a) Sales: |
37.457.839,00 |
41.759.094,00 |
37.830.526,00 |
53.199.111,00 |
51.696.939,00 |
|
|
b) Rendering of services: |
1.941.708,00 |
281.707,00 |
520.092,00 |
212.484,00 |
94.179,00 |
|
|
Returns and Rappel on sales: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.2. Stock increase of
manufactured goods and products in process: |
795.237,00 |
0,00 |
976.547,00 |
0,00 |
0,00 |
|
|
B.3. Works performed by the
company for fixed assets: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.4. Miscellaneous operating
income: |
1.105,00 |
19.893,00 |
40.426,00 |
28.387,00 |
5.761,00 |
|
|
a) Auxiliary income and other from
current management: |
0,00 |
0,00 |
0,00 |
300,00 |
969,00 |
|
|
b) Grants: |
1.105,00 |
19.893,00 |
40.426,00 |
28.087,00 |
4.792,00 |
|
|
c) Liabilities and charges
provisions surplus: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.I. PÉRDIDAS DE EXPLOTACIÓN
(A.1+A.2+A.3+A.4+A.5-A.6-B.1-B.2-B.3-B.4): |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.5. Income from equity
investment: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
a) In companies of the group: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) In associated companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
c) Third parties: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.6. Income from other marketable
securities and long-term receivables: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
a) From companies of the group: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) From associated companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
c) From companies out of the
group: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.7. Miscellaneous interests or
similar income: |
12.947,00 |
1.897,00 |
0,00 |
92,00 |
482,00 |
|
|
a) From companies of the group: |
12.947,00 |
1.871,00 |
0,00 |
0,00 |
0,00 |
|
|
b) From associated companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
c) Miscellaneous interests: |
0,00 |
26,00 |
0,00 |
92,00 |
482,00 |
|
|
d) Profit on financial
investment: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.8. Exchange positive
differences: |
0,00 |
10.353,00 |
0,00 |
27.840,00 |
0,00 |
|
|
B.II. NEGATIVE FINANCIAL RESULTS
(A.7+A.8+A.9-B.5-B.6-B.7-B.8): |
25.163,00 |
0,00 |
16.284,00 |
0,00 |
6.892,00 |
|
|
B.III. LOSSES ON ORDINARY
ACTIVITIES ( B.I + B.II - A.I - A.II ): |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.9.Profit on disposal of both
tangible and intangible fixed assets and securities portfolio: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.10. Profit on transactions with
own shares and debentures: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.11. Capital grants transferred
to profit and loss: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.12. Extraordinary income: |
99.509,00 |
2.132,00 |
0,00 |
215.210,00 |
58.394,00 |
|
|
B.13. Income and profit of former
financial years: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.IV. NEGATIVE EXTRAORDINARY
RESULTS (A.10+A.11+A.12+A.13+A.14-B.9-B.10-B.11-B.12-B.13): |
0,00 |
48.264,00 |
30.656,00 |
0,00 |
0,00 |
|
|
B.V. LOSSES BEFORE TAXES
(B.III+B.IV-A.III-A.IV): |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.VI. RESULT OF THE PERIOD
(LOSSES) (B.V+A.15+A.16): |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
MERCANTILE REGISTRY.
|
CASHFLOW
STATEMENT
|
|
|
|
|
Model:
Normal
>
Source of information: Data contained in this section is taken from the
information declared in the Annual Accounts submitted to the Trade Register.
|
|
2014 |
2013 |
2012 |
2011 |
2010 |
|
|
1. Fiscal year result before
taxes.: 61100 |
1.449.122,00 |
2.163.319,00 |
939.540,00 |
422.300,00 |
463.512,00 |
|
|
2. Results adjustments.: 61200 |
1.999.418,00 |
2.338.359,00 |
2.709.995,00 |
2.012.456,00 |
2.842.676,00 |
|
|
a) Fixed Assets Amortization
(+).: 61201 |
1.974.256,00 |
2.350.609,00 |
2.380.703,00 |
2.439.498,00 |
2.460.426,00 |
|
|
b) Obsolescence Allowances (+/-).
: 61202 |
0,00 |
0,00 |
293.365,00 |
0,00 |
-19.870,00 |
|
|
c) Variation in Provision (+/-).
: 61203 |
0,00 |
0,00 |
0,00 |
-403.939,00 |
360.713,00 |
|
|
e) Results on disposal of fixed
assets (+/-). : 61205 |
0,00 |
0,00 |
19.643,00 |
4.829,00 |
34.514,00 |
|
|
g) Financial income (-).: 61207 |
-12.947,00 |
0,00 |
0,00 |
-92,00 |
-482,00 |
|
|
h) Financial Expenses (+). :
61208 |
198,00 |
-1.897,00 |
5.311,00 |
0,00 |
0,00 |
|
|
i) Exchange differences (+/-). :
61209 |
37.912,00 |
-10.353,00 |
10.973,00 |
-27.840,00 |
7.375,00 |
|
|
3. Changes in current capital
equity.: 61300 |
611.593,00 |
-378.086,00 |
-3.449.663,00 |
524.809,00 |
362.228,00 |
|
|
a) Stock (+/-).: 61301 |
-1.030.501,00 |
357.269,00 |
-1.563.735,00 |
3.499.902,00 |
4.298.700,00 |
|
|
d) Debtors and other accounts
receivable (+/-). : 61302 |
1.881.643,00 |
613.062,00 |
-1.840.041,00 |
567.949,00 |
1.705.919,00 |
|
|
c) Other current assets (+/-). :
61303 |
0,00 |
-27.763,00 |
-43.598,00 |
-900.870,00 |
-3.662.667,00 |
|
|
d) Creditors and other accounts
payable (+/-). : 61304 |
-707.415,00 |
-1.129.842,00 |
288.241,00 |
-2.642.172,00 |
-1.979.724,00 |
|
|
e) Other current liabilities
(+/-).: 61305 |
470.843,00 |
-190.812,00 |
-63.022,00 |
0,00 |
0,00 |
|
|
f) Other non-current assets and
liabilities (+/-).: 61306 |
-2.978,00 |
0,00 |
-227.508,00 |
0,00 |
0,00 |
|
|
4. Other cash flows for operating
activities.: 61400 |
-904.489,00 |
-376.993,00 |
-5.311,00 |
92,00 |
482,00 |
|
|
a) Interest payments (-). : 61401 |
-198,00 |
0,00 |
-5.311,00 |
0,00 |
0,00 |
|
|
c) Interest collection (+). :
61403 |
12.947,00 |
1.897,00 |
0,00 |
92,00 |
482,00 |
|
|
d) Income tax payment collection
(payments) (+/-).: 61404 |
-917.239,00 |
-378.890,00 |
0,00 |
0,00 |
0,00 |
|
|
5. Operating activity cash flows (1
+ 2 + 3 + 4) : 61500 |
3.155.643,00 |
3.746.599,00 |
194.561,00 |
2.959.657,00 |
3.668.898,00 |
|
|
6. Payments for investment (-).:
62100 |
-3.576.133,00 |
-4.146.500,00 |
-2.162.328,00 |
-2.958.954,00 |
-2.317.069,00 |
|
|
a) Companies of the group and
affiliates. : 62101 |
0,00 |
-1.991.421,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Intangible fixed assets. :
62102 |
-9.990,00 |
-2.711,00 |
-7.755,00 |
343,00 |
-30.716,00 |
|
|
c) Fixed assets. : 62103 |
-3.566.101,00 |
-2.152.368,00 |
-2.154.573,00 |
-2.959.297,00 |
-2.286.353,00 |
|
|
e) Other financial assets. :
62105 |
-41,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
7. Divestment payment collection
(+). : 62200 |
2.313.983,00 |
77.397,00 |
0,00 |
254,00 |
11.582,00 |
|
|
a) Companies of the group and
affiliates. : 62201 |
2.234.152,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
c) Fixed assets. : 62203 |
79.831,00 |
77.397,00 |
0,00 |
254,00 |
11.582,00 |
|
|
8. Investment activity cash flows
(6 + 7) minus Amortization: 62300 |
-1.262.150,00 |
-4.069.103,00 |
-2.162.328,00 |
-2.958.700,00 |
-2.305.487,00 |
|
|
9. Payment collection and
payments for equity instruments. : 63100 |
0,00 |
0,00 |
-10.266,00 |
0,00 |
0,00 |
|
|
b) Amortization of assets
instruments (-). : 63102 |
0,00 |
0,00 |
-10.266,00 |
0,00 |
0,00 |
|
|
10. Payment collection and
payments for financial liabilities instruments.: 63200 |
16.622,00 |
894.219,00 |
1.976.955,00 |
0,00 |
0,00 |
|
|
a) Issuance : 63201 |
16.622,00 |
894.219,00 |
1.976.955,00 |
0,00 |
0,00 |
|
|
3. Debts incurred with companies
of the group and affiliates (+).: 63204 |
16.622,00 |
894.219,00 |
0,00 |
0,00 |
0,00 |
|
|
4. Special characteristic debts (+).
: 63205 |
0,00 |
0,00 |
1.976.955,00 |
0,00 |
0,00 |
|
|
11. Payments from dividends and
remunerations from other assets instruments. : 63300 |
-1.694.463,00 |
-527.527,00 |
0,00 |
0,00 |
-1.363.809,00 |
|
|
a) Dividends (-).: 63301 |
-1.694.463,00 |
-527.527,00 |
0,00 |
0,00 |
-1.363.809,00 |
|
|
12. Cash flows for financing
activities (9+10+11).: 63400 |
-1.677.841,00 |
366.692,00 |
1.966.689,00 |
0,00 |
-1.363.809,00 |
|
|
D) EFFECT OF EXCHANGE RATE
CHANGES: 64000 |
-37.912,00 |
10.353,00 |
0,00 |
0,00 |
0,00 |
|
|
E) NET INCREASE/DECREASE OF CASH
OR EQUIVALENT ASSETS (+/-5+/-8+/12+/-D) : 65000 |
177.740,00 |
54.541,00 |
-1.078,00 |
957,00 |
-398,00 |
|
|
Cash or equivalent assets as of beginning
of the fiscal year.: 65100 |
54.925,00 |
384,00 |
1.461,00 |
503,00 |
902,00 |
|
|
Cash or equivalent assets as of
end of the fiscal year.: 65200 |
232.665,00 |
54.925,00 |
384,00 |
1.461,00 |
504,00 |
|
|
FINANCIAL
DIAGNOSIS
|
|
|
|
|
> Economic-Financial Comparative Analysis
Data used in the following ratios and
indicators is taken from the Annual Accounts submitted by the company to the
TRADE REGISTER.
>
Comparison within the Sector
|
Cash
Flow |
2014 |
2013 |
Variación 2014 - 2013 |
|||
|
|
Empresa |
Sector |
Empresa |
Sector |
Empresa |
Sector |
|
Cash
Flow over Sales: |
0,00 % |
0,05 % |
0,00 % |
0,01 % |
|
252,34 % |
|
EBITDA
over Sales: |
9,34 % |
12,76 % |
10,82 % |
11,37 % |
-13,72 % |
12,21 % |
|
Cash
Flow Yield: |
0,00 % |
0,02 % |
0,00 % |
0,01 % |
|
281,05 % |
|
Profitability |
2014 |
2013 |
Variación 2014 - 2013 |
|||
|
|
Empresa |
Sector |
Empresa |
Sector |
Empresa |
Sector |
|
Operating
economic profitability: |
4,56 % |
9,24 % |
7,40 % |
6,88 % |
-38,38 % |
34,21 % |
|
Total
economic profitability: |
3,42 % |
5,16 % |
4,97 % |
3,76 % |
-31,23 % |
37,15 % |
|
Financial
profitability: |
2,47 % |
7,92 % |
4,63 % |
4,25 % |
-46,79 % |
86,41 % |
|
Margin:
|
3,49 % |
7,97 % |
5,11 % |
6,72 % |
-31,71 % |
18,61 % |
|
Mark-up:
|
3,43 % |
7,20 % |
5,14 % |
4,51 % |
-33,34 % |
59,72 % |
|
Solvency |
2014 |
2013 |
Variación 2014 - 2013 |
|||
|
|
Empresa |
Sector |
Empresa |
Sector |
Empresa |
Sector |
|
Liquidity:
|
0,04 |
0,15 |
0,01 |
0,13 |
341,98 |
10,89 |
|
Acid
Test: |
2,42 |
0,89 |
2,89 |
0,87 |
-16,30 |
2,50 |
|
Working
Capital / Investment: |
0,38 |
0,03 |
0,43 |
0,05 |
-11,76 |
-50,58 |
|
Solvency:
|
3,60 |
1,20 |
3,84 |
1,18 |
-6,10 |
2,17 |
|
Indebtedness |
2014 |
2013 |
Variación 2014 - 2013 |
|||
|
|
Empresa |
Sector |
Empresa |
Sector |
Empresa |
Sector |
|
Indebtedness
level: |
0,19 |
1,31 |
0,19 |
1,39 |
-2,29 |
-6,15 |
|
Borrowing
Composition: |
0,01 |
1,20 |
0,01 |
1,01 |
-37,57 |
18,76 |
|
Repayment
Ability: |
37,34 |
24,19 |
127,37 |
94,63 |
-70,68 |
-74,44 |
|
Warranty:
|
6,39 |
1,77 |
6,26 |
1,73 |
1,97 |
2,65 |
|
Generated
resources / Total creditors: |
0,48 |
0,09 |
0,58 |
0,08 |
-18,03 |
8,34 |
|
Efficiency |
2014 |
2013 |
Variación 2014 - 2013 |
|||
|
|
Empresa |
Sector |
Empresa |
Sector |
Empresa |
Sector |
|
Productivity:
|
1,35 |
2,06 |
1,49 |
1,85 |
-9,60 |
11,17 |
|
Turnover
of Collection Rights : |
11,27 |
5,62 |
7,82 |
5,00 |
44,09 |
12,39 |
|
Turnover
of Payment Entitlements: |
5,38 |
3,75 |
4,70 |
3,63 |
14,56 |
3,27 |
|
Stock
rotation: |
5,85 |
9,15 |
7,30 |
7,35 |
-19,81 |
24,55 |
|
Assets
turnover: |
1,31 |
1,16 |
1,45 |
1,02 |
-9,78 |
13,15 |
|
Borrowing
Cost: |
0,00 |
2,97 |
0,00 |
2,87 |
|
3,19 |
>
Trend of indicators under the General Accounting Plan of 2007 (2014, 2013,
2012, 2011, 2010)
|
Cash
Flow |
2014 |
2013 |
2012 |
2011 |
2010 |
|
Cash
Flow over Sales: |
0,00 % |
0,00 % |
0,00 % |
0,00 % |
0,00 % |
|
EBITDA
over Sales: |
9,34 % |
10,82 % |
8,78 % |
4,91 % |
5,57 % |
|
Cash
Flow Yield: |
0,00 % |
0,00 % |
0,00 % |
0,00 % |
0,00 % |
|
Profitability |
2014 |
2013 |
2012 |
2011 |
2010 |
|
Operating
economic profitability: |
4,56 % |
7,40 % |
3,25 % |
0,68 % |
1,37 % |
|
Total
economic profitability: |
3,42 % |
4,97 % |
2,24 % |
1,04 % |
1,07 % |
|
Financial
profitability: |
2,47 % |
4,63 % |
2,25 % |
0,55 % |
0,78 % |
|
Margin:
|
3,49 % |
5,11 % |
2,52 % |
0,34 % |
0,80 % |
|
Mark-up:
|
3,43 % |
5,14 % |
2,48 % |
0,39 % |
0,78 % |
|
Solvency |
2014 |
2013 |
2012 |
2011 |
2010 |
|
Liquidity:
|
0,04 |
0,01 |
0,00 |
0,00 |
0,00 |
|
Acid
Test: |
2,42 |
2,89 |
2,72 |
3,03 |
2,00 |
|
Working
Capital / Investment: |
0,38 |
0,43 |
0,42 |
0,41 |
0,38 |
|
Solvency:
|
3,60 |
3,84 |
3,66 |
3,82 |
2,89 |
|
Indebtedness |
2014 |
2013 |
2012 |
2011 |
2010 |
|
Indebtedness
level: |
0,19 |
0,19 |
0,19 |
0,18 |
0,26 |
|
Borrowing
Composition: |
0,01 |
0,01 |
0,01 |
0,01 |
0,01 |
|
Repayment
Ability: |
37,34 |
127,37 |
-6.372,07 |
6.388,44 |
-22.718,28 |
|
Warranty:
|
6,39 |
6,26 |
6,16 |
6,66 |
4,80 |
|
Generated
resources / Total creditors: |
0,48 |
0,58 |
0,42 |
0,52 |
0,54 |
|
Efficiency |
2014 |
2013 |
2012 |
2011 |
2010 |
|
Productivity:
|
1,35 |
1,49 |
1,39 |
1,27 |
1,27 |
|
Turnover
of Collection Rights : |
11,27 |
7,82 |
6,41 |
12,87 |
10,98 |
|
Turnover
of Payment Entitlements: |
5,38 |
4,70 |
4,79 |
6,41 |
4,12 |
|
Stock
rotation: |
5,85 |
7,30 |
6,43 |
11,99 |
6,81 |
|
Assets
turnover: |
1,31 |
1,45 |
1,29 |
2,01 |
1,72 |
|
Borrowing
Cost: |
0,00 |
0,00 |
0,08 |
0,00 |
0,00 |
COMPARATIVE
SECTORIAL BALANCE
|
|
|
|
|
Sector-based
Comparison under the rules of the New General Accounting Plan.
|
|
Variación - |
|
|
|
Empresa |
Sector |
|
|
Variación - |
|
|
|
Empresa |
Sector |
|
|
Variación - |
|
|
|
Empresa |
Sector |
|
News
|
|
ABC |
14/12/2013 |
|
La
planta de Toledo de Reig Jofré se convierte en referente a nivel mundial |
|
|
Companies
related |
|
|
LABORATORIO REIG JOFRE SA EN
LIQUIDACION |
|
|
Public
Tenders and Works Won
|
|
Organisation
that calls the tender: |
|
CIUDAD AUTONOMA DE CEUTA |
|
Objective
of Tender: |
|
SUMINISTRO DE DIVERSAS VACUNAS
CON DESTINO A LA CONSEJERIA DE SANIDAD Y CONSUMO. |
|
Date
Awarded: |
|
30/12/2002 |
|
Cost: |
|
52.233,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD Y SERVICIOS
SOCIALES DE LA COMUNIDAD AUTONOMA DE GALICIA |
|
Objective
of Tender: |
|
ADQUISICION, MEDIANTE SUMINISTRO
SUCESIVO, DE VACUNAS, PARA EL PERIODO 2002/2003, PARA EL PROGRAMA GALLEGO DE
VACUNACIONES |
|
Date
Awarded: |
|
03/10/2002 |
|
Cost: |
|
345.690,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
INSTITUTO CATALAN DE LA SALUD ICS |
|
Objective
of Tender: |
|
SUMINISTRO PARA EL HOSPITAL
UNIVERSITARIO VALL D`HEBRON |
|
Date
Awarded: |
|
17/09/2002 |
|
Cost: |
|
208.750,77 EURO. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO LA PAZ |
|
Objective
of Tender: |
|
ADQUISICION DE MEDICAMENTOS Y
FACTORES DE COAGULACION |
|
Date
Awarded: |
|
09/09/2002 |
|
Cost: |
|
211.215,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
SERVICIO ARAGONES DE SALUD |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS DESTINADAS
AL PROGRAMA DE VACUNACIONES DE LA COMUNIDAD AUTONOMA DE ARAGON AŃO 2002. |
|
Date
Awarded: |
|
17/07/2002 |
|
Cost: |
|
307.705,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
SERVICIO ARAGONES DE SALUD |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS PARA LA
CAMPAŃA DE VACUNACIONES 2002 |
|
Date
Awarded: |
|
17/07/2002 |
|
Cost: |
|
307.705,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
SERVICIO ARAGONES DE SALUD |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS DESTINADAS
A LA CAMPAŃA DE VACUNACIONES DE LA COMUNIDAD AUTONOMA DE ARAGON, AŃO 2002. 4
LOTES |
|
Date
Awarded: |
|
17/07/2002 |
|
Cost: |
|
307.705,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
DEPARTAMENTO DE SANIDAD DE LA
COMUNIDAD AUTONOMA DEL PAIS VASCO |
|
Objective
of Tender: |
|
SUMINISTRO DE 11.000 DOSIS DE VACUNA
COMBINADA DIFTERIA-TETANOS-TOSFERINA ACELULAR (DTPA), CON DESTINO A LAS
SUBDIRECCIONES DE SALUD PUBLICA DE ARABA, BIZKAIA Y GIPUZKOA. |
|
Date
Awarded: |
|
09/07/2002 |
|
Cost: |
|
92.510,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
SERVICIO ANDALUZ DE SALUD SAS |
|
Objective
of Tender: |
|
SUMINISTRO DE 865 000 DOSIS DE
VACUNA ANTIGRIPAL PARA EL PROGRAMA DE VACUNACIONES DE ANDALUCIA. |
|
Date
Awarded: |
|
04/07/2002 |
|
Cost: |
|
594.500,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL SEVERO OCHOA DE LEGANES |
|
Objective
of Tender: |
|
SUMINISTRO DE MEDICAMENTOS |
|
Date
Awarded: |
|
18/06/2002 |
|
Cost: |
|
3 863 221,75 EUR (IMPORTE
COMPARTIDO POR VARIAS EMPRESAS CONTRATISTAS) |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL SEVERO OCHOA DE LEGANES |
|
Objective
of Tender: |
|
MEDICAMENTOS |
|
Date
Awarded: |
|
18/06/2002 |
|
Cost: |
|
95.851,58 EURO. |
|
|
|
Organisation
that calls the tender: |
|
SERVICIO ANDALUZ DE SALUD SAS |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS CON
COMPONENTE DTP PARA EL PVA |
|
Date
Awarded: |
|
12/06/2002 |
|
Cost: |
|
4.380.644,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
SERVICIO ANDALUZ DE SALUD SAS |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS CON
COMPONENTE DTP PARA EL PVA. |
|
Date
Awarded: |
|
12/06/2002 |
|
Cost: |
|
4.380.644,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
DEPARTAMENTO DE SANIDAD Y
SEGURIDAD SOCIAL DE LA COMUNIDAD AUTONOMA DE CATALUŃA |
|
Objective
of Tender: |
|
ADQUISICION DE VACUNAS . CAMPAŃA
2002 |
|
Date
Awarded: |
|
07/06/2002 |
|
Cost: |
|
2.173.995,32 EURO. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO VIRGEN DEL
ROCIO |
|
Objective
of Tender: |
|
SUMINISTRO DE MEDICAMENTOS DE
EXCLUSIVIDAD DE LOS HH.UU. VIRGEN DEL ROCIO. 18 LOTES |
|
Date
Awarded: |
|
04/06/2002 |
|
Cost: |
|
119.661,50 EURO. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO VIRGEN DEL
ROCIO |
|
Objective
of Tender: |
|
SUMINISTRO DE MEDICAMENTOS DE
EXCLUSIVIDAD DE LOS HH.UU. VIRGEN DEL ROCIO. 16 LOTES |
|
Date
Awarded: |
|
04/06/2002 |
|
Cost: |
|
131.594,46 EURO. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO VIRGEN DEL
ROCIO |
|
Objective
of Tender: |
|
SUMINISTRO DE MEDICAMENTOS DE
EXCLUSIVIDAD DE LOS HOSPITALES UNIVERSITARIOS VIRGEN DEL ROCIO. |
|
Date
Awarded: |
|
04/06/2002 |
|
Cost: |
|
131.594,46 EURO. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO VIRGEN DEL
ROCIO |
|
Objective
of Tender: |
|
SUMINISRI DE MEDICAMENTOS DE
EXCLUSIVIDAD DE LOS HOSPITALES UNIVERSITTARIOS VIRGEN DEL ROCIO |
|
Date
Awarded: |
|
04/06/2002 |
|
Cost: |
|
119.661,50 EURO. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO DE GETAFE |
|
Objective
of Tender: |
|
SUMINISTRO DE MEDICAMENTOS PARA
EL HOSPITAL UNIVERSITARIO DE GETAFE. |
|
Date
Awarded: |
|
29/05/2002 |
|
Cost: |
|
3.356,16 EURO. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO DE GETAFE |
|
Objective
of Tender: |
|
MEDICAMENTOS |
|
Date
Awarded: |
|
29/05/2002 |
|
Cost: |
|
3.356,16 EURO. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD DE LA COMUNIDAD
AUTONOMA DE VALENCIA |
|
Objective
of Tender: |
|
ADQUISICION DE VACUNAS DESTINADAS
A LOS PROGRAMAS DE VACUNACIONES DE LA CONSELLERIA DE SANIDAD |
|
Date
Awarded: |
|
16/05/2002 |
|
Cost: |
|
4.353.450,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
SUBSECRETARIA PARA LOS RECURSOS
DE SANIDAD DE LA CONSEJERIA DE SANIDAD DE VALENCIA |
|
Objective
of Tender: |
|
ADQUISICION DE VACUNAS DESTINADAS
A LOS PROGRAMAS DE VACUNACIONES DE LA CONSEJERIA DE SANIDAD |
|
Date
Awarded: |
|
16/05/2002 |
|
Cost: |
|
4.353,45 EURO. |
|
|
|
Organisation
that calls the tender: |
|
DIRECCION GENERAL DE SALUD
PUBLICA DE LA CONSEJERIA DE SANIDAD Y BIENESTAR SOCIAL DE CASTILLA Y LEON |
|
Objective
of Tender: |
|
SUMINISTRO DE 180.000 DOSIS DE VACUNA
CONTRA EL TETANOS-DIFTERIA TIPO ADULTOS, DENTRO DEL PROGRAMA DE VACUNACIONES
DEL CALENDARIO OFICIAL PARA 2002 |
|
Date
Awarded: |
|
06/05/2002 |
|
Cost: |
|
360.000,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
DIRECCION GENERAL DE LA POLICIA
DEL MINISTERIO DE INTERIOR |
|
Objective
of Tender: |
|
ADQUUISICION DE VACUNAS
ANTIHEPATITIS A + B PARA CAMPAŃA DE VACUNACION DE FUNCIONARIOS POLICIALES |
|
Date
Awarded: |
|
29/04/2002 |
|
Cost: |
|
144.746,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL GENERAL YAGÜE DE BURGOS |
|
Objective
of Tender: |
|
SUMINISTRO DE ANTIBIOTICOS Y
ANTIFUNGICOS |
|
Date
Awarded: |
|
22/04/2002 |
|
Cost: |
|
14.687,09 EURO. |
|
|
|
Organisation
that calls the tender: |
|
SERVICIO NAVARRO DE SALUD |
|
Objective
of Tender: |
|
SUMINISTRO DE APROXIMADAMENTE 26
000 DOSIS DE VACUNA ANTIPOLIOMIELITICA, 13 300 DOSIS DE VACUNA MENINGITIS C
CONJUGADA, 15 600 DOSIS DE VACUNA ANTIHAEMOPHILUS TIPO B + VACUNA DTP-HEPATITIS
B, 12 000 DOSIS DE VACUNA TRIPLE VIRICA, 5 200 DOSIS DE VACUNA DTP ACELULAR,
5 000 DOSIS DE VACUNA DIFTERIA-TETANOS INFANTIL DITE, 35 000 DOSIS DE VACUNA
DIFTERIA-TETANOS ADULTO TEDI, 15 600 DOSIS DE VACUNA ANTIHEPATITIS B
INFANTIL, 6 000 DOSIS DE VACUNA ANTIHEPATITIS B ADULTOS, 24 000 DOSIS DE
TUBERCULINAS |
|
Date
Awarded: |
|
17/04/2002 |
|
Cost: |
|
LOTE 1: 1,74; LOTE 3: 15,33; LOTE
5: 7,81; LOTE 8: 5,85 |
|
|
|
Organisation
that calls the tender: |
|
SERVICIO NAVARRO DE SALUD |
|
Objective
of Tender: |
|
ANTIPOLIOMIELITICA, MENINGITIS C
CONJUGADA, ANTIHAEMOPHILUS B+DTP-HEPATITIS B, TRIPLE VIRICA, DTP ACELULAR,
DIFTERIA-TETANOS INFANTIL Y ADULTO, ANTIHEPATITIS B INFANTIL Y ADULTOS
TUBERCULINAS. |
|
Date
Awarded: |
|
17/04/2002 |
|
Cost: |
|
908.730,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
SERVICIO NAVARRO DE SALUD |
|
Objective
of Tender: |
|
SUMINISTRO DE DIVERSAS VACUNAS
CON DESTINO AL INSTITUTO DE SALUD PUBLICA, PARA LA CAMPAŃA DE VACUNACION DEL
AŃO 2002. |
|
Date
Awarded: |
|
17/04/2002 |
|
Cost: |
|
SEGUN OBJETO. VER IMAGEN. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO PUERTA DEL
MAR |
|
Objective
of Tender: |
|
SUMINISTRO DE PRODUCTOS
FARMACEUTICOS |
|
Date
Awarded: |
|
15/04/2002 |
|
Cost: |
|
62.791,67 EURO. |
|
|
|
Organisation
that calls the tender: |
|
INSTITUTO CATALAN DE LA SALUD ICS |
|
Objective
of Tender: |
|
SUMINISTRO DE PRODUCTOS
FARMACEUTICOS |
|
Date
Awarded: |
|
12/04/2002 |
|
Cost: |
|
208.750,77 EURO. |
|
|
|
Organisation
that calls the tender: |
|
SERVICIO REGIONAL DE SALUD DE LA
CONSEJERIA DE SANIDAD DE MADRID |
|
Objective
of Tender: |
|
ADQUISICION DE VACUNAS PARA LA
CAMPAŃA DE VACUNACION INFANTIL PARA EL AŃO 2002: 7 LOTES. |
|
Date
Awarded: |
|
11/04/2002 |
|
Cost: |
|
5.412.850,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SALUD Y SERVICIOS
SANITARIOS DE LA COMUNIDAD AUTONOMA DEL PRINCIPADO DE ASTURIAS |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNA ANTIPOLIOMIELITICA
ORAL TRIVALENTE; TRIPLE VIRICA; ANTITETANICA-B INFANTIL Y ADULTOS HAEMOPHILUS
INFLUENZAE TIPO B; TRIPLE BACTERIANA + HEPATITIS -B; TETRAVLENTE HAEMOPHILUS
INFLUENZAE TIPO B, CONJUGADA CON DIFTERIA- TETANOS-TOSFERINA; TRIPLE
BACTERIANA; DOBLE BACTERIANA ADULTOS, CONJUGADA FRENTE A LA MENINGITIS C,
TETANOS MONOVALENTE, TUBERCULINA 2UT, RT23 (PPD) Y VACUNA ANTIGRIPAL. |
|
Date
Awarded: |
|
08/04/2002 |
|
Cost: |
|
SEGUN LOTE. VER IMAGEN. |
|
|
|
Organisation
that calls the tender: |
|
COMPLEJO HOSPITALARIO LA
MANCHA-CENTRO DE ALCAZAR DE SAN JUAN |
|
Objective
of Tender: |
|
SUMINISTRO DE MEDICAMENTOS Y
ASIMILADOS |
|
Date
Awarded: |
|
03/04/2002 |
|
Cost: |
|
107.777,01 EURO. |
|
|
|
Organisation
that calls the tender: |
|
DIRECCION GENERAL DE SALUD
PUBLICA DE LA CONSEJERIA DE SANIDAD Y BIENESTAR SOCIAL DE CASTILLA Y LEON |
|
Objective
of Tender: |
|
SUMINISTRO DE 15.000 DOSIS DE
VACUNA FRENTE A LA DIFTERIA, TETANOS, TOSFERINA ACELULAR DENTRO DEL PROGRAMA
DE VACUNACIONES DEL CALENDARIO OFICIAL PARA EL AŃO 2002 |
|
Date
Awarded: |
|
02/04/2002 |
|
Cost: |
|
117.150,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE HACIENDA Y ECONOMIA
DE LA COMUNIDAD AUTONOMA DE LA RIOJA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS
SISTEMATICAS PARA EL AŃO 2002 EN LA COMUNIDAD AUTONOMA DE LA RIOJA. 8 LOTES. |
|
Date
Awarded: |
|
27/03/2002 |
|
Cost: |
|
SEGUN LOTES. VER IMAGEN. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL GENERAL YAGÜE DE BURGOS |
|
Objective
of Tender: |
|
SUMINISTRO DE ANTIBIOTICOS Y
ANTIFUNGICOS |
|
Date
Awarded: |
|
26/03/2002 |
|
Cost: |
|
114.730,60 EURO. |
|
|
|
Organisation
that calls the tender: |
|
ATENCION PRIMARIA DE MADRID |
|
Objective
of Tender: |
|
SUMINISTRO DE MEDICAMENTOS Y
PRODUCTOS FARMACEUTICOS |
|
Date
Awarded: |
|
08/03/2002 |
|
Cost: |
|
4.139,29 EURO. |
|
|
|
Organisation
that calls the tender: |
|
ATENCION PRIMARIA DE MADRID |
|
Objective
of Tender: |
|
MEDICAMENTOS V 05/02. GRUPO CPA: 24.4. |
|
Date
Awarded: |
|
08/03/2002 |
|
Cost: |
|
4.139,29 EURO. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD Y CONSUMO
DE LA COMUNIDAD AUTONOMA DE LA REGION DE MURCIA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS PARA EL PROGRAMA
DE VACUNACIONES DE LA REGION DE MURCIA, PARA EL AŃO 2002. 9 LOTES. |
|
Date
Awarded: |
|
06/03/2002 |
|
Cost: |
|
SEGUN LOTE VER PRESUPUESTO EN
IMAGEN |
|
|
|
Organisation
that calls the tender: |
|
DEPARTAMENTO DE SANIDAD DE LA COMUNIDAD
AUTONOMA DEL PAIS VASCO |
|
Objective
of Tender: |
|
SUMINISTRO DE 38.000 DOSIS DE
COMBINADA DIFTERIA-TETANOS-PERTUSSIS CELULA ENTERA - HEPATITIS B Y
HAEMOPHILUS INFLUENZAE TIPO B (DTPW-HB+HIB) , CON DESTINO A LAS
SUBDIRECCIONES DE SALUD PUBLICA DE ARABA, BIZKAIA Y GIPUZKOA. |
|
Date
Awarded: |
|
04/03/2002 |
|
Cost: |
|
570.760,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
GOBIERNO DE CANTABRIA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS DESTINADAS AL
CUMPLIMIENTO DEL CALENDARIO VACUNAL DE CANTABRIA EN EL AŃO 2002 |
|
Date
Awarded: |
|
28/02/2002 |
|
Cost: |
|
447.241,40 EURO. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO 12 DE
OCTUBRE |
|
Objective
of Tender: |
|
PRINCIPIOS ACTIVO DEL LABORATORIO
SMITHKLINE BECCHAM |
|
Date
Awarded: |
|
26/02/2002 |
|
Cost: |
|
291.102,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO MARQUES DE
VALDECILLA |
|
Objective
of Tender: |
|
STENT CORONARIOS. |
|
Date
Awarded: |
|
25/02/2002 |
|
Cost: |
|
MINIMO: 1.072,81 EUROS; MAXIMO:
1.081,82 EUROS |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO MARQUES DE
VALDECILLA |
|
Objective
of Tender: |
|
ONCOLOGICOS FARMACIA. |
|
Date
Awarded: |
|
25/02/2002 |
|
Cost: |
|
1468483,42 EUROS. A REPARTIR
ENTRE LAS EMPRESAS ADJUDICATARIAS |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO MARQUES DE
VALDECILLA |
|
Objective
of Tender: |
|
ONCOLOGICOS. FARMACIA. |
|
Date
Awarded: |
|
25/02/2002 |
|
Cost: |
|
MINIMO/MAXIMO: 0,600230
EUR/581,09 EUR |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO VIRGEN DE
LAS NIEVES |
|
Objective
of Tender: |
|
SUMINISTRO DE MEDICAMENTOS EXCLUSIVOS
DE LAS FIRMAS GLAXO WELLCOME SA Y SMITHKLINE BEECHAM SA. |
|
Date
Awarded: |
|
18/02/2002 |
|
Cost: |
|
76.654,40 EURO. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL SAN JUAN DE LA CRUZ |
|
Objective
of Tender: |
|
SUMINISTRO DE MEDICAMENTOS |
|
Date
Awarded: |
|
12/02/2002 |
|
Cost: |
|
63.386,20 EURO. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL SAN JUAN DE LA CRUZ |
|
Objective
of Tender: |
|
SUMINISTRO DE MEDICAMENTOS. |
|
Date
Awarded: |
|
12/02/2002 |
|
Cost: |
|
63.386,20 EURO. |
|
|
|
Organisation
that calls the tender: |
|
GOBIERNO DE CANTABRIA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS DESTINADAS
AL CUMPLIMIENTO DEL CALENDARIOVACUNAL DE CANTABRIA EN EL AŃO 2002 |
|
Date
Awarded: |
|
11/02/2002 |
|
Cost: |
|
1.257.452,40 EUROS; PRESUPUESTO
COMPARTIDO ENTRE VARIOS CONTRATISTAS |
|
|
|
Organisation
that calls the tender: |
|
DEPARTAMENTO DE SANIDAD DE LA
COMUNIDAD AUTONOMA DEL PAIS VASCO |
|
Objective
of Tender: |
|
SUMINISTRO DE 56.000 DOSIS DE
VACUNA ANTIPOLIOMIELITICA ORAL TRIVALENTE TIPO SABIN Y 8.100 DOSIS DE VACUNA
FRENTE A HEPATITIS B ADULTO |
|
Date
Awarded: |
|
11/02/2002 |
|
Cost: |
|
106.400,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD Y CONSUMO
DE LA COMUNIDAD AUTONOMA DE LAS ISLAS BALEARES |
|
Objective
of Tender: |
|
SUMINISTRO DE DTP+HEP B,
ANTIHEMOPPHILUS B, DTPA+HIB, TD, POLIO, MENINGITIS MENINGOC, C, TV Y HEPATITIS
B INFANTIL, PARA EL DESARROLLO DE LA CAMPAŃA DE VACUNACION 2002 DE LA
COMUNIDAD AUTONOMA DE LES ILLES BALEARS (279 000 DOSIS TOTAL, DIVIDIDAS EN 8
LOTES SEGUN PLIGOS). |
|
Date
Awarded: |
|
07/02/2002 |
|
Cost: |
|
SEGUN LOTES. VER IMAGEN. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD Y CONSUMO
DE LA COMUNIDAD AUTONOMA DE LAS ISLAS BALEARES |
|
Objective
of Tender: |
|
SUMINISTRO VACUNAS SIGUIENTES:
35.000 DOSIS DE DTP+HEP B; 35.000 DOSIS DE HIB TIPO B; 10.000 DOSIS DE DTPA+HIB;
60.000 DOSIS DE TD; 60.000 DOSIS DE POLIO ORAL; 35.000 DOSIS DE MENING. C;
20.000 DOSIS DE TV; 24.000 DOSIS DE HB ADOLESC. |
|
Date
Awarded: |
|
07/02/2002 |
|
Cost: |
|
VER IMAGEN |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD Y CONSUMO
DE LA COMUNIDAD AUTONOMA DE LAS ISLAS BALEARES |
|
Objective
of Tender: |
|
SUMINISTRO DE LAS VACUNAS
SIGUIENTES: DTP+HEPB, ANTIHEMOPHILUS B, DTP+HIB, TD, POLIO, MENINGITIS,
MENINGOC C, TV Y HEPATITIS B INFANTIL |
|
Date
Awarded: |
|
07/02/2002 |
|
Cost: |
|
SEGUN LOTE. VER IMAGEN. |
|
|
|
Organisation
that calls the tender: |
|
COMPLEJO HOSPITALARIO DE JAEN |
|
Objective
of Tender: |
|
ADQUISICION DE AUGMENTINE Y
HYCAMTIN. |
|
Date
Awarded: |
|
07/02/2002 |
|
Cost: |
|
68.957,64 EURO. |
|
|
|
Organisation
that calls the tender: |
|
DIRECCION GENERAL DE LA GUARDIA
CIVIL DEL MINISTERIO DE INTERIOR |
|
Objective
of Tender: |
|
SUMINISTRO DE DOSIS DE VACUNA
CONTRA LA HEPATITIS - B |
|
Date
Awarded: |
|
06/02/2002 |
|
Cost: |
|
102.160,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
COMPLEJO HOSPITALARIO CARLOS HAYA |
|
Objective
of Tender: |
|
SUMINISTRO DE PRODUCTOS
FARMACEUTICOS XIV |
|
Date
Awarded: |
|
05/02/2002 |
|
Cost: |
|
144.419,75 EURO. |
|
|
|
Organisation
that calls the tender: |
|
COMPLEJO HOSPITALARIO CARLOS HAYA |
|
Objective
of Tender: |
|
SUMINISTRO DE PRODUCTOS
FARMACEUTICOS XIV. |
|
Date
Awarded: |
|
05/02/2002 |
|
Cost: |
|
144.419,75 EURO. |
|
|
|
Organisation
that calls the tender: |
|
ATENCION PRIMARIA DE MALLORCA |
|
Objective
of Tender: |
|
ESPECIALIDADES FARMACEUTICAS Y
FARMACEUTICO-GENERICAS |
|
Date
Awarded: |
|
02/02/2002 |
|
Cost: |
|
3.888,00 EURO. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD Y CONSUMO
DE LA COMUNIDAD AUTONOMA DE EXTREMADURA |
|
Objective
of Tender: |
|
ADQUISICION DE VACUNAS, AŃO 2002. |
|
Date
Awarded: |
|
31/01/2002 |
|
Cost: |
|
PRESUPUESTO SEGUN LOTE; VER
IMAGEN |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD Y CONSUMO
DE LA COMUNIDAD AUTONOMA DE EXTREMADURA |
|
Objective
of Tender: |
|
ADQUISICION DE VACUNAS, AŃO 2002. |
|
Date
Awarded: |
|
31/01/2002 |
|
Cost: |
|
IMPORTE TOTAL A REPARTIR ENTRE ADJUDICATARIAS:
1841662,26 EUR. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO VIRGEN DE
LAS NIEVES |
|
Objective
of Tender: |
|
SUMINISTRO DE MEDICAMENTOS
EXCLUSIVOS DE GLAXO WELLCOME, SA Y SMITHKLINE BEECHAM SA. |
|
Date
Awarded: |
|
04/01/2002 |
|
Cost: |
|
76.654,40 EURO. |
|
|
|
Organisation
that calls the tender: |
|
DIRECCION GENERAL DE
INSTITUCIONES PENITENCIARIAS DEL MINISTERIO DE INTERIOR |
|
Objective
of Tender: |
|
SUMINISTRO DE 18.450 DOSIS DE VCUNA
ANTIGRIPAL DE VIRUS FRACCIONADOS INACTIVADOS |
|
Date
Awarded: |
|
13/06/2001 |
|
Cost: |
|
64.447,37 EURO. |
|
|
|
Organisation
that calls the tender: |
|
GOBIERNO DE CANTABRIA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS DESTINADAS AL
CUMPLIMIENTO DEL CALENDARIO VACUNAL EN EL AŃO 2001. |
|
Date
Awarded: |
|
18/04/2001 |
|
Cost: |
|
119510520 PTAS A COMPARTIR POR
VARIAS EMPRESAS |
|
|
|
Organisation
that calls the tender: |
|
GOBIERNO DE CANTABRIA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS DESTINADAS
AL CUMPLIMIENTO DEL CALENDARIO VACUNAL REGIONAL EN EL AŃO 2001 |
|
Date
Awarded: |
|
18/04/2001 |
|
Cost: |
|
119.510.520 PTAS; PRESUPUESTO
COMPARTIDO ENTRE VARIOS CONTRATISTAS |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE PRESIDENCIA DE LA
COMUNIDAD AUTONOMA DE CANTABRIA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS DESTINADAS
AL CUMPLIMIENTO DEL CALENDARIO VACUNAL REGIONAL EN EL AŃO 2001 |
|
Date
Awarded: |
|
01/04/2001 |
|
Cost: |
|
10.359.600 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD DE LA
COMUNIDAD AUTONOMA DE VALENCIA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS DESTINADAS
A LOS PROGRAMAS DE VACUNACIONES DEL AŃO 2001 DE LA CONSELLERIA DE SANIDAD. |
|
Date
Awarded: |
|
22/03/2001 |
|
Cost: |
|
209.060.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CIUDAD SANITARIA Y UNIVERSITARIA
DE BELLVITGE |
|
Objective
of Tender: |
|
SUMINISTRO DE PRODUCTOS
FARMACEUTICOS. |
|
Date
Awarded: |
|
20/03/2001 |
|
Cost: |
|
1.376.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
INSTITUTO CATALAN DE LA SALUD ICS |
|
Objective
of Tender: |
|
SUMINISTRO DE PRODUCTOS
FARMACEUTICOS |
|
Date
Awarded: |
|
20/03/2001 |
|
Cost: |
|
1.376.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SALUD Y SERVICIOS
SANITARIOS DE LA COMUNIDAD AUTONOMA DEL PRINCIPADO DE ASTURIAS |
|
Objective
of Tender: |
|
VACUNA ANTIPOLIOMELITICA EN 5 O 10
DOSIS Y VACUNA TRIPLE VIRICA; . VACUNA ANTIHEPATITIS B DE 0 A 14 AŃOS Y
VACUNA ANTIHEPATITIS B DE ADULTOS; C. VACUNA H MOPHILUS INFLUENZAE TIPO B Y
VACUNA TRIPLE BACTERIANA DIFTERIA, TETANOS, TOSFERINA COMPLETA HEPATITIS B;
VACUNA TETRAVALENTE H MOPHILUS INFLUENZAE TIPO B CONJUGADA CON VACUNA CONTRA
DIFTERIA TETANOS TOSFERINA COMPLETA Y VACUNA TRIPLE BACTERIANA DIFTERIA,
TETANOS, TOSFERINA ACELULAR. VACUNA DOBLE BACTERIANA ADULTOS TETANOS DIFTERIA
, VER IMAGEN |
|
Date
Awarded: |
|
13/03/2001 |
|
Cost: |
|
SEGUN LOTES. VER IMAGEN. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SALUD Y SERVICIOS
SANITARIOS DE LA COMUNIDAD AUTONOMA DEL PRINCIPADO DE ASTURIAS |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNA ANTIPOLIOMELITICA
ORAL TRIVALENTE; TRIPLE VIRICA; ANTITETANICA B INFANTIL Y ADULTOS;
HAEMOPHILUS INFLUENZAE TIPO B; TRIPLE BACTERIANA HEPATITIS B; TETRAVALENTE
HAEMOPHILUS INFLUENZAE TIPO B, CONJUGADA CON DIFTERIA TETANOS TOSFERINA;
TRIPLE BACTERIANA; DOBLE BACTERIANA ADULTOS, CONJUGADA FRENTE A LA MENINGITIS
C; ANTIGRIPAL |
|
Date
Awarded: |
|
13/03/2001 |
|
Cost: |
|
PRESUPUESTO SEGUN LOTE; VER
IMAGEN |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD Y CONSUMO DE
LA COMUNIDAD AUTONOMA DE LA REGION DE MURCIA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS PARA EL
PROGRAMA DE VACUNACIONES DE LA REGION DE MURCIA DE 2001 |
|
Date
Awarded: |
|
06/03/2001 |
|
Cost: |
|
VER IMPORTE POR LOTES EN LA
IMAGEN |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD Y CONSUMO
DE LA COMUNIDAD AUTONOMA DE LA REGION DE MURCIA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS PARA EL
PROGRAMA DE VACUNACIONES DE LA REGION DE MURCIA |
|
Date
Awarded: |
|
06/03/2001 |
|
Cost: |
|
22.100.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD Y CONSUMO
DE LA COMUNIDAD AUTONOMA DE LA REGION DE MURCIA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS PARA EL PROGRAMA
DE VACUNACIONES DE LA REGION DE MURCIA |
|
Date
Awarded: |
|
06/03/2001 |
|
Cost: |
|
26.125.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD Y CONSUMO
DE LA COMUNIDAD AUTONOMA DE LA REGION DE MURCIA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS PARA EL
PROGRAMA DE VACUNACIONES DE LA REGION DE MURCIA |
|
Date
Awarded: |
|
06/03/2001 |
|
Cost: |
|
43.700.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD Y CONSUMO DE
LA COMUNIDAD AUTONOMA DE LA REGION DE MURCIA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS PARA EL
PROGRAMA DE VACUNACIONES DE LA REGION DE MURCIA |
|
Date
Awarded: |
|
06/03/2001 |
|
Cost: |
|
83.600.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD Y CONSUMO
DE LA COMUNIDAD AUTONOMA DE LA REGION DE MURCIA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS PARA EL
PROGRAMA DE VACUNACIONES DE LA REGION DE MURCIA |
|
Date
Awarded: |
|
06/03/2001 |
|
Cost: |
|
24.000.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD Y CONSUMO
DE LA COMUNIDAD AUTONOMA DE LA REGION DE MURCIA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS PARA EL PROGRAMA
DE VACUNACIONES DE LA REGION DE MURCIA, AŃO 2001 |
|
Date
Awarded: |
|
06/03/2001 |
|
Cost: |
|
PRESUPUESTO SEGUN LOTE; VER
IMAGEN |
|
|
|
Organisation
that calls the tender: |
|
DEPARTAMENTO DE SANIDAD DE LA
COMUNIDAD AUTONOMA DEL PAIS VASCO |
|
Objective
of Tender: |
|
SUMINISTRO DE 59.500 DOSIS DE
VACUNA COMBINADA DTP HB Y VACUNA FRENTE A HAEMOPHILUS INFLUENZAE B DTPW HB
HIB . |
|
Date
Awarded: |
|
02/03/2001 |
|
Cost: |
|
2.150 PTA POR DOSIS |
|
|
|
Organisation
that calls the tender: |
|
CORPORACION SANITARIA PARC TAULI |
|
Objective
of Tender: |
|
MATERIAL SANITARIO DIVERSO |
|
Date
Awarded: |
|
28/02/2001 |
|
Cost: |
|
3.811.704 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CORPORACION SANITARIA PARC TAULI |
|
Objective
of Tender: |
|
ANTIINFECCIOSOS |
|
Date
Awarded: |
|
28/02/2001 |
|
Cost: |
|
3.811.704 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CORPORACION SANITARIA PARC TAULI |
|
Objective
of Tender: |
|
SUMINISTRO DE MATERIAL SANITARIO |
|
Date
Awarded: |
|
28/02/2001 |
|
Cost: |
|
3.811.704 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CONSORCIO SANITARIO DE TERRASSA |
|
Objective
of Tender: |
|
SUMINISTRO DE MEDICAMENTOS |
|
Date
Awarded: |
|
28/02/2001 |
|
Cost: |
|
17.906.899 PTS. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO MARQUES DE
VALDECILLA |
|
Objective
of Tender: |
|
PRODUCTOS ANTIBIOTICOS |
|
Date
Awarded: |
|
23/02/2001 |
|
Cost: |
|
MINIMO 6 ESP; MAXIMO 4 198 ESP |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO MARQUES DE
VALDECILLA |
|
Objective
of Tender: |
|
SUMINISTRO DE PRODUCTOS
ANTIBIOTICOS |
|
Date
Awarded: |
|
23/02/2001 |
|
Cost: |
|
27.909.151 PTS. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITALES VALL D' HEBRON |
|
Objective
of Tender: |
|
SUMINISTRO DE MEDICAMENTOS. |
|
Date
Awarded: |
|
15/02/2001 |
|
Cost: |
|
25.153.818 PTS. |
|
|
|
Organisation
that calls the tender: |
|
DEPARTAMENTO DE SANIDAD Y SEGURIDAD
SOCIAL DE LA COMUNIDAD AUTONOMA DE CATALUŃA |
|
Objective
of Tender: |
|
ADQUISICION DE VACUNA ANTIGRIPAL. |
|
Date
Awarded: |
|
13/02/2001 |
|
Cost: |
|
84.903.950 PTS. |
|
|
|
Organisation
that calls the tender: |
|
DEPARTAMENTO DE SANIDAD Y SEGURIDAD
SOCIAL DE LA COMUNIDAD AUTONOMA DE CATALUŃA |
|
Objective
of Tender: |
|
ADQUISICION DE 8.400 DOSIS DE
VACUNA ANTIHEPATITIS A B. |
|
Date
Awarded: |
|
13/02/2001 |
|
Cost: |
|
31.752.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO MARQUES DE
VALDECILLA |
|
Objective
of Tender: |
|
SUMINISTRO DE PRODUCTOS
ONCOLOGICOS |
|
Date
Awarded: |
|
12/02/2001 |
|
Cost: |
|
3.251.145 PTS. |
|
|
|
Organisation
that calls the tender: |
|
ATENCION PRIMARIA DE MALLORCA |
|
Objective
of Tender: |
|
SUMINISTRO DE ESPECIALIDADES
FARMACEUTICAS/GENERICAS. |
|
Date
Awarded: |
|
12/02/2001 |
|
Cost: |
|
1.169.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO MARQUES DE
VALDECILLA |
|
Objective
of Tender: |
|
SUMINISTRO DE PRODUCTOS
ONCOLOGICOS |
|
Date
Awarded: |
|
09/02/2001 |
|
Cost: |
|
MINIMO 7,58 ESP; MAXIMO 134
828,95 ESP |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD Y BIENESTAR
SOCIAL DE LA COMUNIDAD AUTONOMA DE CASTILLA Y LEON |
|
Objective
of Tender: |
|
SUMINISTRO DE 36000 DOSIS DE
VACUNAS COMBINADA DIFTERIA TENTANOS Y TOSFERINA |
|
Date
Awarded: |
|
23/01/2001 |
|
Cost: |
|
61.200.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD DE LA
COMUNIDAD AUTONOMA DE CASTILLA-LA MANCHA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS PARA
PROGRAMAS DE INMUNIZACION INFANTIL Y DE ADULTOS PARA EL AŃO 2001 |
|
Date
Awarded: |
|
17/01/2001 |
|
Cost: |
|
29.007.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD DE LA
COMUNIDAD AUTONOMA DE CASTILLA-LA MANCHA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS PARA PROGRAMAS
DE INMUNIZACION INFANTIL Y DE ADULTOS PARA EL AŃO 2001 |
|
Date
Awarded: |
|
17/01/2001 |
|
Cost: |
|
86.815.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD DE LA
COMUNIDAD AUTONOMA DE CASTILLA-LA MANCHA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS PARA
PROGRAMAS DE INMUNIZACION INFANTIL Y DE ADULTOS PARA EL AŃO 2001 |
|
Date
Awarded: |
|
17/01/2001 |
|
Cost: |
|
39.400.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD DE LA
COMUNIDAD AUTONOMA DE CASTILLA-LA MANCHA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS PARA
PROGRAMAS DE INMUNIZACION INFANTIL Y DE ADULTOS PARA EL AŃO 2001 |
|
Date
Awarded: |
|
17/01/2001 |
|
Cost: |
|
28.860.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
CONSEJERIA DE SANIDAD DE LA
COMUNIDAD AUTONOMA DE CASTILLA-LA MANCHA |
|
Objective
of Tender: |
|
SUMINISTRO DE VACUNAS PARA
PROGRAMAS DE INMUNIZACION INFANTIL Y DE ADULTOS PARA EL AŃO 2001 |
|
Date
Awarded: |
|
17/01/2001 |
|
Cost: |
|
162.500 PTS. |
|
|
|
Organisation
that calls the tender: |
|
SERVICIO VASCO DE SALUD |
|
Objective
of Tender: |
|
SUMINISTRO DEL MEDICAMENTO
CLOXACILINA ORAL E INYECTABLE. |
|
Date
Awarded: |
|
08/01/2001 |
|
Cost: |
|
10.880.000 PTS. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO VIRGEN DE
LA ARRIXACA |
|
Objective
of Tender: |
|
MEDICAMENTOS PARA ANTIBITICOS DE
DIFERENTES PRONCIPIOS ACTIVOS |
|
Date
Awarded: |
|
05/01/2001 |
|
Cost: |
|
31.151.240 PTS. |
|
|
|
Organisation
that calls the tender: |
|
HOSPITAL UNIVERSITARIO VIRGEN DE
LA ARRIXACA |
|
Objective
of Tender: |
|
ADQUISICION DE MEDICAMENTOS PARA
ANTIBIOTICOS DE DIFERENTES PRINCIPIOS ACTIVOS PARA EL HOSPITAL UNIVERSITARIO
``VIRGEN DE LA ARRIXACA``. |
|
Date
Awarded: |
|
05/01/2001 |
|
Cost: |
|
31.151.240 PTS. |
|
|
|
Organisation
that calls the tender: |
|
SERVICIO VASCO DE SALUD |
|
Objective
of Tender: |
|
MEDICAMENTO TOPOTECAN DCI
INYECTABLE PARA LAS ORGANIZACIONES SANITARIAS DEL EPDP. |
|
Date
Awarded: |
|
03/01/2001 |
|
Cost: |
|
52.018.332 PTS. |
|
Detail
of Subsidies appearing in Balances Memories
|
|
|
|
|
|
Entity |
ORGANISMO NO ESPECIFICADO |
|
Subsidy Concept |
Subvención a la explotación |
|
Status |
CONCEDIDA |
|
Amount Granted |
1.105,00 |
|
Notes |
Subvención para la formación de
empleo. |
|
Entity |
CANM |
|
Subsidy Concept |
Subvención a la explotación |
|
Status |
CONCEDIDA |
|
Amount Granted |
40.426,00 |
|
Notes |
Subvención para la formación de empleo. |
|
Entity |
FUNDACION TRIPARTITA |
|
Subsidy Concept |
Subvención a la explotación |
|
Status |
CONCEDIDA |
|
Amount Granted |
28.087,00 |
|
Notes |
Subvención para la formación de
empleo. |
|
Entity |
FUNDACION TRIPARTITA |
|
Subsidy Concept |
Subvención a la explotación |
|
Status |
CONCEDIDA |
|
Amount Granted |
4.791,00 |
|
Research
Summary
|
|
It is a corporation that was
established many years ago, which gives it sufficient experience in the sector
of activities it carries out and it has good reputation amongst consulted
references. Though its invoicing has decreased with a percentage of 6,28 % in
2014 in comparison to the previous year. It presents a positive Working Fund,
which enables the company to comply with its short term payment obligations. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.64.78 |
|
|
1 |
Rs.99.54 |
|
Euro |
1 |
Rs.73.08 |
INFORMATION DETAILS
|
Analysis Done by
: |
RAS |
|
|
|
|
Report Prepared
by : |
ASH |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment record
(10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.